

26/12/2006, 10525820e.trn

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTASXY1626


PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'HCAPLUS' AT 11:50:29 ON 15 DEC 2006  
FILE 'HCAPLUS' ENTERED AT 11:50:29 ON 15 DEC 2006  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	260.56	1650.38
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-37.50	-114.00

=> d ed abs ibib hitstr 1-37

L21 ANSWER 1 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 28 Aug 2006  
 GI




AB Provided is a process for the preparation of N-monosubstituted  $\beta$ -amino acids. Sulfonates of formula I. Compds. of formula I wherein R1 is (un)substituted C6-20 aryl or (un)substituted C4-12 heteroaryl; R2 is C1-4 alkyl or (un)substituted C6-20 aryl; R3 is selected from the group consisting of C1-18 alkyl, C6-20 cycloalkyl, C6-20 aryl and C7-20 aralkyl residues, and the process for preparing compds. of formula I are claimed. The process comprising the steps of a) reacting a Me ketone, a primary amine, formaldehyde and a sulfonic acid, at a pressure above 1.5 bar, optionally in an organic solvent, said organic solvent optionally containing water, to afford N-monosubstituted  $\beta$ -amino ketone sulfonates of formula II, wherein R1, R2 and R3 are as defined above, and b) asym. hydrogenating said sulfonates in the presence of a base and a catalyst, comprising a transition metal and a diphosphine ligand, in a polar solvent, optionally in the presence of water.

ACCESSION NUMBER: 2006:866581 HCAPLUS  
 DOCUMENT NUMBER: 145:271387  
 TITLE: Process for the preparation of enantiomerically pure 1-substituted-3-amino alcohols using methyl ketones, primary amines, formaldehydes and sulfonic acids  
 INVENTOR(S): Brieden, Walter; Clausen, Martin; McGarrity, John; Mettler, Hanspeter; Michel, Dominique  
 PATENT ASSIGNEE(S): Lonza A.-G., Switz.  
 SOURCE: PCT Int. Appl., 38pp.  
 CODEN: PIIXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006087166	A1	20060824	WO 2006-EPI334	20060214
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,			

L21 ANSWER 1 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2  
 CRN 75-75-2  
 CMF C H4 O3 S

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 1 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MN, MZ, NA, SD, SL, SZ, T2, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

EP 1693371 A1 20060823 EP 2005-3657 20050221  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU

PRIORITY APPLN. INFO.: EP 2005-3657 A 20050221


OTHER SOURCE(S): CASREACT 145:271387; MARPAT 145:271387

IT 906812-53-1P 906812-54-2P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (product; Preparation of enantiomerically pure sulfonate salts of substituted amino acids, and amino ketones by reacting Me ketones, primary amines, formaldehyde and sulfonic acids)

RN 906812-53-1 HCAPLUS  
 CN 1-Propanone, 3-(methylamino)-1-phenyl-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 27152-62-1  
 CMF C10 H13 N O



CM 2

CRN 75-75-2  
 CMF C H4 O3 S



RN 906812-54-2 HCAPLUS  
 CN 1-Propanone, 3-(ethylamino)-1-phenyl-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 38115-24-1  
 CMF C11 H15 N O

L21 ANSWER 2 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 08 Dec 2005


AB A regioselective and highly efficient synthesis of 6-amino-substituted pyridin-2(1H)-ones is presented. In situ generated propiolic acid chloride was used for the cyclization of acyclic  $\beta$ -keto N,S-acetals to afford the heterocyclic core. Substitution by amines led to a

access of the target compds.

ACCESSION NUMBER: 2005:1284045 HCAPLUS  
 DOCUMENT NUMBER: 144:150218  
 TITLE: Efficient synthesis of 6-amino-substituted pyridin-2(1H)-ones using in situ generated propiolic acid chloride  
 AUTHOR(S): Schirok, Hartmut; Alonso-Alija, Cristina; Michels, Martin  
 CORPORATE SOURCE: Pharma Research, Bayer HealthCare AG, Wuppertal, 42096, Germany  
 SOURCE: Synthesis (2005), (18), 3085-3094  
 PUBLISHER: Georg Thieme Verlag  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 144:150218  
 IT 56617-74-4  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (regioselective preparation of 6-amino-2-pyridinones via heterocyclization  
 of  $\beta$ -keto N,S-acetals with in situ generated propiolic acid chloride and substitution reaction with amines)

RN 56617-74-4 HCAPLUS


CN Benzenepropanethioamide, N-methyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

26/12/2006, 10525820e.trn

L21 ANSWER 3 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 29 Nov 2005  
 AB The keto-enol-enethiol tautomerism in 3-oxo-3-R1-N-R2-propanethioamides under vacuum and in acetone was studied in terms of d. functional theory. It was established that the equilibrium depends on the structure of the 3-oxo-3-R1-N-R2-propanethioamides and on the nature of the solvent, but the most stable form is as a rule the keto form stabilized by an intramol. hydrogen bond.  
 ACCESSION NUMBER: 2005-1252888 HCAPLUS  
 DOCUMENT NUMBER: 145-45584  
 TITLE: Quantum-Chemical Investigation of Keto-enol-enethiol Tautomerism in 3-oxo-3-R1-N-R2-propanethioamides  
 AUTHOR(S): Il'chenko, N. N.; Britsau, V. N.; Lozinskii, M. O.  
 CORPORATE SOURCE: Institute of Cellular Biology and Genetic Engineering,  
 National Academy of Sciences of Ukraine, Kiev. 03143, Ukraine  
 SOURCE: Theoretical and Experimental Chemistry (2005), 41(5), 284-289  
 PUBLISHER: Springer  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 56617-74-4 876857-90-8 876857-91-9  
 RL: PRP (Properties)  
 (DFT study on keto-enol-enethiol tautomerism in 3-oxo-3-R1-N-R2-propanethioamides)  
 RN 56617-74-4 HCAPLUS  
 CN Benzene propanethioamide, N-methyl-β-oxo- (9CI) (CA INDEX NAME)




RN 876857-90-8 HCAPLUS  
 CN Benzene propanethioamide, 4-methoxy-N-methyl-β-oxo- (9CI) (CA INDEX NAME)



RN 876857-91-9 HCAPLUS  
 CN Benzene propanethioamide, N-methyl-4-nitro-β-oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 4 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 18 Nov 2005  
 GI



AB Title compds., such as I [wherein R1 = (un)substituted (hetero)aryl, aralkyl, etc.; R2 = H or (un)substituted alkyl; R3, R4 = halo, alkoxy, nitro, etc.; R5 = (un)substituted alkyl, alkoxy, amino, etc.; m = 0-4, with limitations, and pharmaceutically acceptable salts, prodrugs or solvates thereof] were prepared as modulators of GABA<sub>A</sub> and nicotinic acetylcholine receptors. For instance, 2,2-dimethyl-1,3-dioxane-4,6-dione underwent condensation successively with 2-chlorobenzoyl chloride in the presence of DMAP, propylamine, N,N-dimethylformamide dimethylacetil and 4-(trifluoromethyl)aniline to give II. Several biol. assays were executed. Representative I showed inhibition against GABA receptor with IC<sub>50</sub> of 0.01 - 0.20 μM in the (35S)-TBPS binding assay. Therefore, the invented compds. and their pharmaceutical compns. are useful for the treatment of CNS disorders amenable to modulation of GABA<sub>A</sub> and nicotinic acetylcholine receptors.


ACCESSION NUMBER: 2005-1220692 HCAPLUS  
 DOCUMENT NUMBER: 143-477643  
 TITLE: Preparation of enaminones as modulators of GABA<sub>A</sub> and nicotinic acetylcholine receptors  
 INVENTOR(S): Hogenkamp, Derk J.; Johnstone, Timothy B. C.; Gee, Kelvin W.  
 PATENT ASSIGNEE(S): The Regents of the University of California, USA  
 SOURCE: PCT Int. Appl. 66 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005108347	A2	20051117	WO 2005-US15669	20050505
WO 2005108347	A3	20060706		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML

Young, Shawquia, Page 3

L21 ANSWER 3 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT


FORMAT

L21 ANSWER 4 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 MR, NE, SN, TD, TG  
 PRIORITY APPLN. INFO.: US 2004-569465P P 20040506

OTHER SOURCE(S): MARPAT 143-477643  
 IT 869555-11-3P 869555-14-6P 869555-16-8P  
 869555-17-9P 869555-57-7P 869555-58-8P  
 869555-61-3P 869555-62-4P 869555-79-3P  
 869555-86-2P 869555-87-3P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of enaminones as modulators of GABA<sub>A</sub> and nicotinic acetylcholine receptors)  
 RN 869555-11-3 HCAPLUS  
 CN Benzene propanamide, 2-chloro-N-ethyl-α-[(4-iodophenylamino)methylene]-β-oxo- (9CI) (CA INDEX NAME)




RN 869555-14-6 HCAPLUS  
 CN Benzene propanamide, 2-chloro-N-ethyl-β-oxo-α-(pyrazinylamino)- (9CI) (CA INDEX NAME)




RN 869555-16-8 HCAPLUS  
 CN Benzene propanamide, 2-chloro-N-ethyl-β-oxo-α-[(4H-1,2,4-triazol-4-ylamino)methylene]- (9CI) (CA INDEX NAME)

L21 ANSWER 4 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN


(Continued)



RN 869555-17-9 HCAPLUS  
CN Benzenepropanamide, 2-chloro-N-ethyl- $\alpha$ -[(3-isoxazolylamino)methylene]- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 869555-57-7 HCAPLUS  
CN Benzenepropanamide, 2-chloro- $\alpha$ -[(4-chlorophenyl)amino]methylene-N-ethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 869555-58-8 HCAPLUS  
CN Benzenepropanamide, 2-chloro- $\alpha$ -[(4-ethoxyphenyl)amino]methylene-N-ethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)


L21 ANSWER 4 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 869555-61-3 HCAPLUS  
CN Benzenepropanamide, 2-chloro- $\alpha$ -[(4-iodophenyl)amino]methylene-N-methyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 869555-62-4 HCAPLUS  
CN Benzenepropanamide, 2-chloro- $\alpha$ -[(4-chlorophenyl)amino]methylene-N-methyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 869555-79-3 HCAPLUS  
CN Benzenepropanamide, 2-chloro- $\alpha$ -[(4-cyanophenyl)amino]methylene-N-ethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 869555-86-2 HCAPLUS  
CN Benzenepropanamide, 2-chloro-N-ethyl- $\alpha$ -[(1-(4-

L21 ANSWER 4 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
fluorophenyl)ethyl]amino)methylene]- $\beta$ -oxo- (9CI) (CA INDEX NAME)

RN 869555-87-3 HCAPLUS  
CN Benzenepropanamide, 2-chloro-N-ethyl- $\beta$ -oxo- $\alpha$ -[(1-phenylethyl)amino]methylene- (9CI) (CA INDEX NAME)



IT 869555-09-9P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of enamines as modulators of GABA and nicotinic acetylcholine receptors)  
RN 869555-09-9 HCAPLUS  
CN Benzenepropanamide, 2-chloro- $\alpha$ -[(dimethylamino)methylene]-N-ethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)




L21 ANSWER 5 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 04 Nov 2005

AB Ru-SYNPHOS and Ru-DIFLUORPHOS catalysts were efficiently used for the synthesis of a wide variety of chiral  $\beta$ -hydroxy amides via asym.hydrogenation of the corresponding  $\beta$ -keto amides.

ACCESSION NUMBER: 2005:1174285 HCAPLUS  
DOCUMENT NUMBER: 144:69604  
TITLE: Ru-SYNPHOS and Ru-DIFLUORPHOS: Highly efficient catalysts for practical preparation of  $\beta$ -hydroxy amides  
AUTHOR(S): Touati, Ridha; Gmiza, Thouraya; Jeulin, Severine; Deport, Coralia; Ratovelomanana-Vidal, Virginie; Ben Hassine, Bechir; Genet, Jean-Pierre  
CORPORATE SOURCE: Laboratoire de Synthese Organique Asymétrique et Catalyse Homogène, Faculté des Sciences de Monastir, Monastir, 5019, Tunisia  
SOURCE: Synlett (2005), (16), 2478-2482  
CODEN: SYNE; ISSN: 0936-5214  
PUBLISHER: Georg Thieme Verlag  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 144:69604  
IT 197852-01-0  
RL: PRP (Properties); RCT (Reactant); RACT (Reactant or reagent)  
(hydrogenation kinetics; preparation of  $\beta$ -hydroxy amides by asym.  
hydrogenation of  $\beta$ -keto amides using ruthenium Synphos and  
Difluorphos catalysts)


RN 197852-01-0 HCAPLUS

CN Benzenepropanamide, N-methyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)

IT 123987-17-7 871578-97-1

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of  $\beta$ -hydroxy amides by asym. hydrogenation of  $\beta$ -keto amides using ruthenium Synphos and Difluorphos catalysts)


RN 123987-17-7 HCAPLUS

CN Benzenepropanamide, N,4-dimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)

RN 871578-97-1 HCAPLUS

CN Benzenepropanamide, 4-fluoro-N-methyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 6 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L21 ANSWER 6 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 14 Sep 2005

AB The improved method of the synthesis of 3-oxo-3-R1-N-R2-propanethioamides is proposed based upon (i) the preparation of sodium enolates of 1,3-dicarbonyl compds. ( $\text{RICOCH} \cdot \text{COMe} \cdot \text{Na}^+$ ), (ii) their subsequent thiocarbonylation with  $\text{R}_2\text{N-C(=S)}$  and neutralization to afforded acetyl derive.  $\text{RICOCH}(\text{Ac})\text{CSNHR}_2$ , and (iii) hydrolysis to afford the title compds.  $\text{RICOCH}_2\text{CSNHR}_2$ . The ratio

of keto- and enol forms of 3-oxo-3-R1-N-R2-propanethioamides in different solvents was studied by the methods of NMR  $^1\text{H}$  spectroscopy and IR spectroscopy.

ACCESSION NUMBER: 2005:994248 HCAPLUS

DOCUMENT NUMBER: 144:253708

TITLE: Improved method for the synthesis and keto-enol tautomerism of 3-oxo-3-R1-N-R2-propanethioamides

AUTHOR(S): Britsun, V. M.; Borisevich, A. M.; Samoilenko, L. S.; Lozinskii, M. O.

CORPORATE SOURCE: Inst. Org. Khim., NAN Ukr., Kiev, Ukraine

SOURCE: Ukrainskii Khimicheskii Zhurnal (Russian Edition) (2005), 71(7-8), 111-116

CODEN: UKZHAU; ISSN: 0041-6045

PUBLISHER: Institut Obshchei i Neorganicheskoi Khimii im. V. I. Vernadskogo NAN Ukrayny

DOCUMENT TYPE: Journal


LANGUAGE: Ukrainian

OTHER SOURCE(S): CASREACT 144:253708

IT 910296-57-0 910296-74-1 910296-87-6

RL: RCT (Reactant); RACT (Reactant or reagent)  
(improved synthesis and keto-enol tautomerism of 3-oxopropanethioamides and solvent and substituent effects thereon)


RN 910296-57-0 HCAPLUS

CN Benzenepropanethioamide,  $\alpha$ -acetyl- $N$ -methyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)


RN 910296-74-1 HCAPLUS

CN Benzenepropanethioamide,  $\alpha$ -acetyl-4-methoxy- $N$ -methyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 6 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 910296-87-6 HCAPLUS  
CN Benzenepropanethioamide,  $\alpha$ -acetyl- $N$ -methyl-4-nitro- $\beta$ -oxo- (9CI)  
(CA INDEX NAME)




IT 56617-74-4P 876857-90-8P 876857-91-9P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(keteo-enol tautomerism; improved synthesis and keto-enol tautomerism of 3-oxopropanethioamides and solvent and substituent effects thereon)

RN 56617-74-4 HCAPLUS  
CN Benzenepropanethioamide,  $N$ -methyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 876857-90-8 HCAPLUS  
CN Benzenepropanethioamide, 4-methoxy- $N$ -methyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 876857-91-9 HCAPLUS  
CN Benzenepropanethioamide,  $N$ -methyl-4-nitro- $\beta$ -oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 7 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 06 Jul 2005  
 AB Polymer-supported chiral ligands were prepared based on Noyori's (1S,2S)- or (1R,2R)-N-(p-tolylsulfonyl)-1,2-diphenylethylenediamine. The combination with [RuCl<sub>2</sub>(p-cymene)]<sub>2</sub> has been shown to exhibit high activities and enantioselectivities for heterogeneous asym. transfer hydrogenation of aromatic ketones with formic acid-triethylamine azeotrope as the hydrogen donor, whereby affording the resp. optically active alcs., the key precursors of chiral fluoxetine. The catalysts can be recovered and reused in three consecutive runs with no significant decline in enantioselectivity. The procedure avoids the plausible contamination of fluoxetine by the toxic transition metal species.  
 ACCESSION NUMBER: 2005:580715 HCAPLUS  
 DOCUMENT NUMBER: 143:248107  
 TITLE: Preparation of polymer-supported Ru-TsDPEN catalysts and use for enantioselective synthesis of (S)-fluoxetine  
 AUTHOR(S): Li, Yangzhou; Li, Zhiming; Li, Feng; Wang, Quanrui; Tao, Fenggang  
 CORPORATE SOURCE: Department of Chemistry, Fudan University, Shanghai, 200433, Peop. Rep. China  
 SOURCE: Organic & Biomolecular Chemistry (2005), 3(14), 2513-2518  
 CODEN: OBCRAK; ISSN: 1477-0520  
 PUBLISHER: Royal Society of Chemistry  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 143:248107  
 IT 197852-01-0  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of polymer-supported Ru-TsDPEN catalysts for enantioselective synthesis of (S)-fluoxetine)  
 RN 197852-01-0 HCAPLUS  
 CN Benzenepropanamide, N-methyl-β-oxo- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 8 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 RN 24206-62-0 HCAPLUS  
 CN 1-Propanone, 1-(4-methoxyphenyl)-3-(methylamino)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 851878-34-7 HCAPLUS  
 CN 1-Propanone, 3-(methylamino)-1-(2-methylphenyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 851878-36-9 HCAPLUS  
 CN 1-Propanone, 1-(3-bromophenyl)-3-(methylamino)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 851878-38-1 HCAPLUS  
 CN 1-Propanone, 1-(4-bromophenyl)-3-(methylamino)-, hydrochloride (9CI) (CA INDEX NAME)


L21 ANSWER 8 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 24 Mar 2005  
 AB Several β-secondary amino ketone hydrochlorides were hydrogenated with remarkably high enantioselectivities by using a rhodium complex containing P-chiral bisphospholane. These results establish a short and practical means for the synthesis of enantiopure N-monosubstituted γ-amino alcs., which are key intermediates in the synthesis of important antidepressants. For example, the bis[di(methyl)ethyl]tetra(hydro-1,1'-bi-1H-isophosphindole)-rhodium-catalyzed stereoselective hydrogenation of 3-(methylaminol)-1-phenyl-1-propanone hydrochloride gave (S)-α-[2-[(methyl)aminoethyl]benzenemethanol, which is a synthetic precursor for (S)-N-methyl-γ-[4-(trifluoromethyl)phenoxy]benzenepropanamine (i.e., (S)-fluoxetine). The synthesis of (S)-[(methyl)aminoethyl]thiophenemethanol, a key synthetic intermediate for (S)-duloxetine, was also reported.

ACCESSION NUMBER: 2005:251916 HCAPLUS  
 DOCUMENT NUMBER: 142:481782  
 TITLE: Practical synthesis of enantiopure γ-amino acids by rhodium-catalyzed asymmetric hydrogenation  
 AUTHOR(S): Liu, Duan; Gao, Wenzhong; Wang, Chunjiang; Zhang, Xumu  
 CORPORATE SOURCE: Department of Chemistry, The Pennsylvania State University, University Park, PA, 16802, USA  
 SOURCE: Angewandte Chemie, International Edition (2005), 44(11), 1687-1689  
 CODEN: ACIEPS; ISSN: 1433-7851  
 PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 142:481782  
 IT 2538-50-3P 34206-62-0P 851878-34-7P  
 851878-36-9P 851878-38-1P 851878-40-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of chiral [(methyl)aminoethyl]arenemethanol by bis[di(methyl)ethyl]tetra(hydro-1,1'-bi-1H-isophosphindole)-rhodium-catalyzed stereoselective hydrogenation using (aryl)[(methyl)amino]propanone hydrochloride as synthetic intermediate)  
 RN 2538-50-3 HCAPLUS  
 CN 1-Propanone, 3-(methylamino)-1-phenyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

L21 ANSWER 8 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl


RN 851878-40-5 HCAPLUS  
 CN 1-Propanone, 1-(2-methoxyphenyl)-3-(methylamino)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


26/12/2006, 10525820e.trn

L21 ANSWER 9 OF 137 HCPLUS COPYRIGHT 2006 ACS on STN  
ED Entered STN: 17 Sep 2004  
GI




AB A series of 11b-substituted 1,6,7,11b-tetrahydropyrimido[6,1-a]-isoquinoline-2,4-diones and 4-thioxo-1,3,4,6,7,11b-hexahydropyrimido[6,1-a]isoquinolin-2-ones, e.g., I, were synthesized, utilizing two alternative strategies for ring closure of tetrahydroisoquinoline intermediates obtained from N-phenethyl enamines.

ACCESSION NUMBER: 2004:757242 HCPLUS  
DOCUMENT NUMBER: 143:26552  
TITLE: Synthesis of some novel 11b-substituted pyrimido[6,1-a]isoquinoline derivatives  
AUTHOR(S): Angelov, Plamen A.; Ivanov, Iliyan I.; Venkov, Atanas  
CORPORATE SOURCE: Department of Organic Chemistry, University of Plovdiv, Plovdiv, 4000, Bulgaria  
SOURCE: Molecules (2004), 9(8), 694-704  
CODEN: MOLEFW; ISSN: 1420-3049  
URL: <http://www.mdpi.org/molecules/papers/90800694.pdf>  
PUBLISHER: Molecular Diversity Preservation International  
DOCUMENT TYPE: Journal; (online computer file)  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 143:26552  
IT 197852-01-0  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of tetrahydroisoquinolinylacetamides via heterocyclization of homoveratritylamine with  $\beta$ -keto amides in the preparation of pyrimidoisoquinoline derivs.)  
RN 197852-01-0 HCPLUS  
CN Benzeneepropanamide, N-methyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)



L21 ANSWER 10 OF 137 HCPLUS COPYRIGHT 2006 ACS on STN  
ED Entered STN: 14 Mar 2004  
GI



AB The invention relates to methods for the enantioselective production of amino alcs.,  $RICH(OH)CH_2(CH_2)nNRH_2$  [R1 = (un)substituted, (un)saturated or aromatic carbocycle or heterocycle (optionally substituted with R3, R4); R2 = H, Cl-20-alkyl; R3, R4 = H, Cl-20-alkyl, Cl-20-alkoxy, aryl, aryloxy, CO2R2, F, Cl, Br, OH, CN, NO2, N(R2)2, NHCOR2; n = 0 - 3], via the enantioselective hydrogenation of amino ketones,  $RICOCH_2(CH_2)nNRH_2$  and is characterized by hydrogenation in the presence of a non-racemic catalyst containing a chiral diphosphine ligand I [R5, R6, R7, R8 = H, Cl-20-alkyl, Cl-20-alkoxy, aryloxy, F, Cl, Br, N(R2)2, NHCOR2; R5R6, R6R7, R7R8 = (CH2)4, CH:CH:CH:CH, etc.; R9, R10 = CSH(R11)m, 2-furyl, cyclohexyl; R11 = H, Cl-20-alkyl, Cl-20-alkoxy, aryl, aryloxy, SO3Na, COR12, F, Cl, N(R12)2, NHCOR12; R12 = H, Cl-20-alkyl; m = 0 - 3] or II [Q = PPh2, P(cyclohexyl)2, P(C6H3(CP3)2-3,5), P(4-methoxy-3,5-dimethylphenyl)2, P(CMe3)2; Y = OH, P(cyclohexyl)2, P(C6H3Me2-3,5)2, P(CMe3)2; Z = H, PPh2; Ph = unsubstituted Ph, C6H4Me-2, C6H4Me-3, C6H4Me-4, C6H3Me2]. Thus, (S)-N-methyl-3-hydroxy-3-(2-thienyl)propanamine was prepared with 92.8% e.e. from 3-(methylamino)-1-(2-thienyl)-1-propanone via asym. hydrogenation in MeOH/PhMe containing catalytic bis(1,5-cyclooctadiene)diruthenium(I) dichloride and (S)-(-)-2,2'-bis[di(p-tolyl)phosphine]-1,1'-binaphthyl.

ACCESSION NUMBER: 2004:203795 HCPLUS  
DOCUMENT NUMBER: 140:253262  
TITLE: Method for the preparation amino alcohols via the enantioselective hydrogenation of amino ketones

L21 ANSWER 9 OF 137 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)  
REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 10 OF 137 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)  
INVENTOR(S): Kralik, Joachim; Fabian, Kai; Muermann, Christoph; Schweickert, Norbert  
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany  
SOURCE: PCT Int. Appl., 27 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004020389	A1	20040311	WO 2003-EP6513	20030801
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YA, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
CA 2496883	AA	20040311	CA 2003-2496883	20030801
AU 2003260347	A1	20040319	AU 2003-260347	20030801
EP 1532100	A1	20050525	EP 2003-790842	20030801
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003013795,	A	20050712	BR 2003-13795	20030801
CN 1678562	A	20051005	CN 2003-820304	20030801
JP 2005536556	T2	20051202	JP 2004-531845	20030801
US 2005261514	A1	20051124	US 2005-525821	20050225
ZA 2005002458	A	20051010	ZA 2005-2458	20050324
PRIORITY APPLN. INFO.:			DE 2002-10240025	A 20020827
			WO 2003-EP6513	W 20030801

OTHER SOURCE(S): CASREACT 140:253262; MARPAT 140:253262  
IT 27152-62-1, 3-(Methylamino)-1-phenyl-1-propanone  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(enantioselective hydrogenation; preparation amino alcs. via the enantioselective hydrogenation of amino ketones with chiral diphosphine ligands)

RN 27152-62-1 HCPLUS

CN 1-Propanone, 3-(methylamino)-1-phenyl- (9CI) (CA INDEX NAME)

O  
Ph-C(=O)-CH2-CH2-NHMe  
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Young, Shawquia, Page 7


26/12/2006, 10525820e.trn

L21 ANSWER 11 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 11 Mar 2004  
 AB R<sub>1</sub>COCH<sub>2</sub>CH<sub>2</sub>NHR<sub>2</sub> (R<sub>1</sub> = (substituted) (unsatd.) residue, aromatic heterocycl., R<sub>2</sub> = alkyl), were prepared by reaction of R<sub>1</sub>COCH<sub>2</sub>CH<sub>2</sub>NR<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>COR<sub>1</sub> (variables as above) with R<sub>2</sub>NH<sub>2</sub>.  
 ACCESSION NUMBER: 2004:198214 HCAPLUS  
 DOCUMENT NUMBER: 140:235592  
 TITLE: Process for the preparation of monoalkylaminoethyl aryl ketones from bis(arylcarboxylethyl)alkylamines.  
 PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany  
 SOURCE: Ger. Offen. 7 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10240026	A1	20040311	DE 2002-10240026	20020827
CA 2497028	AA	20040311	CA 2003-2497028	20030801
WO 2004020391	A1	20040311	WO 2003-EP8514	20030801
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
AU 2003260348	A1	20040319	AU 2003-260348	20030801
EP 1532101	A1	20050525	EP 2003-790843	20030801
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, BE, HU, SE				
BR 2003013796	A	20050927	BR 2003-13796	20030801
CN 1678564	A	20051005	CN 2003-820305	20030801
JP 2005536557	T2	20051202	JP 2004-531846	20030801
US 2006122405	A1	20060608	US 2005-525820	20050225
ZA 2005002457	A	20051025	ZA 2005-2457	20050324
PRIORITY APPLN. INFO.:		DE 2002-10240026	A	20020827
		WO 2003-EP8514	W	20030801


OTHER SOURCE(S): CASREACT 140:235592; MARPAT 140:235592  
 IT 27152-62-1 P RL: IMP (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of monoalkylaminoethyl aryl ketones from bis(arylcarboxylethyl)alkylamines)  
 RN 27152-62-1 HCAPLUS  
 CN 1-Propanone, 3-(methylamino)-1-phenyl- (9CI) (CA INDEX NAME)

L21 ANSWER 12 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 22 Jan 2004  
 AB The first general protocol for the anti-selective reduction of  $\alpha$ -alkyl- $\beta$ -keto amides is described. This simple and efficient methodol. based on an open-chain Finkin-Anh model pathway, allows the isolation of N-mono- and non-substituted anti- $\alpha$ -substituted  $\beta$ -hydroxy amides in good yields and with high diastereoselectivity.  
 ACCESSION NUMBER: 2004:55261 HCAPLUS  
 DOCUMENT NUMBER: 140:217079  
 TITLE: Highly stereoselective reduction of  $\beta$ -keto amides. The first general and efficient approach to N-mono- and non-substituted anti- $\alpha$ -alkyl  $\beta$ -hydroxy amides  
 AUTHOR(S): Bartoli, Giuseppe; Bosco, Marcella; Marcantoni, Enrico; Melchiorre, Paolo; Rinaldi, Samuele; Sambri, Letizia  
 CORPORATE SOURCE: Dipartimento di Chimica Organica "A. Mangini", Universita di Bologna, Bologna, 40136, Italy  
 SOURCE: Synlett (2004), (1), 73-76  
 CODEN: SYNLE; ISSN: 0936-5214  
 PUBLISHER: Georg Thieme Verlag  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 140:217079  
 IT 24956-49-8 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (stereoselective reduction of  $\beta$ -keto amides to N-mono- and non-substituted anti- $\alpha$ -alkyl  $\beta$ -hydroxy amides)  
 RN 24956-49-8 HCAPLUS  
 CN Benzene propanamide, N, $\alpha$ -dimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 11 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




L21 ANSWER 13 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 18 Jan 2004  
 AB The invention relates to a process for the synthesis of N-monosubstituted  $\beta$ -amino alcs. of formula HOCH(R<sub>1</sub>)CH<sub>2</sub>CH<sub>2</sub>NHR<sub>2</sub> and/or an addition salt of a proton acid (wherein R<sub>1</sub> and R<sub>2</sub> independently represent alkyl, cycloalkyl, aryl or aralkyl, each being optionally further substituted with alkoxy and/or halogen) via direct preparation of N-monosubstituted  $\beta$ -amino ketones of R<sub>1</sub>COCH<sub>2</sub>CH<sub>2</sub>NHR<sub>2</sub> and its addition salts of proton acids (wherein R<sub>1</sub> and R<sub>2</sub> are as defined above). Thus, 2-acetylthiophene 25.5, methyamine hydrochloride 14.9, paraformaldehyde 8.2, concentrated HCl 1.0 g, 100 mL ethanol were heated in an autoclave at 110° and a total pressure of 2-2.5 bar for 9 h, followed by removing 50 mL ethanol in vacuo and addition of 200 mL Et acetate under vigorous stirring, and filtration to give 71% 3-(methylamino)-1-(thiophen-2-yl)propan-1-one hydrochloride (I). To a mixture of 10.3 g I and 35 mL ethanol at 4° sodium hydroxide (4.0 g of a 50% aqueous solution) was added in about 5 min and afterwards, 0.95 g neat sodium borohydride in several portions in about 30 min. The resulting suspension was stirred for 4 h at the same temperature, treated dropwise with 10.0 mL acetone in 5 min, stirred for 10 addnl. minutes, treated with 20 mL H<sub>2</sub>O, concentrated about 5 times under vacuum, and extracted with tert-Bu Me ether (2 x 20 mL). The collected organic phases were finally concentrated under vacuum affording an orange oil which crystallized spontaneously after a few hours to give 3-(methylamino)-1-(thiophen-2-yl)propan-1-ol as an orange solid (7.2 g, 84 % yield).  
 ACCESSION NUMBER: 2004:41430 HCAPLUS  
 DOCUMENT NUMBER: 140:93914  
 TITLE: Process for the preparation of N-monosubstituted  $\beta$ -amino alcohols  
 INVENTOR(S): Michel, Dominique  
 PATENT ASSIGNEE(S): Lonza A.-G., Switz.  
 SOURCE: PCT Int. Appl., 28 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004005239	A1	20040115	WO 2003-EP7411	20030709
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
CA 2491472	AA	20040115	CA 2003-2491472	20030709

L21 ANSWER 13 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
AU 2003250924 A1 20040123 AU 2003-250924 20030709  
BR 2003012651 A 20050426 BR 2003-12651 20030709  
EP 1539673 A1 20050615 EP 2003-762669 20030709  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
CN 1665773 A 20050907 CN 2003-816223 20030709  
JP 2005532383 T2 20051027 JP 2004-518758 20030709  
NO 2005000079 A 20050311 NO 2005-79 20050106  
US 2005256318 A1 20051117 US 2005-520362 20050418  
PRIORITY APPLN. INFO.: EP 2002-15229 A 20020709  
WO 2003-EP7411 W 20030709


OTHER SOURCE(S): CASREACT 140:93914; MARPAT 140:93914  
IT 2538-50-3P, 3-(Methylamino)-1-phenylpropan-1-one hydrochloride  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(intermediate; process for preparation of N-monosubstituted  $\beta$ -amino  
alcohols by reduction of N-monosubstituted  $\beta$ -amino ketones)  
RN 2538-50-3 HCAPLUS  
CN 1-Propanone, 3-(methylamino)-1-phenyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L21 ANSWER 14 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
ED Entered STN: 09 Dec 2003  
AB The title compound was prepared from  $\beta$ -bromopropiophenone by amination  
and reduction. The recovery rate of the first step was 82.7%, and that  
of the  
second step was 87.0%. The purity of the product was 99.4%.  
ACCESSION NUMBER: 2003-958874 HCAPLUS  
DOCUMENT NUMBER: 141:90826  
TITLE: Optimization of the technological conditions for  
synthesis of 3-(methylamino)-1-phenylpropyl alcohol  
AUTHOR(S): Zhang, Zheng-guang; Li, Yu-shan  
CORPORATE SOURCE: Institute of Chemistry and Life Science, Three Gorges  
University, Yichang, 443002, Peop. Rep. China  
Jilin Huagong Xueyuan Xuebao (2003), 20(3), 17-18  
SOURCE: Jilin Huagong Xueyuan Xuebao Bianjibu  
PUBLISHER: Journal  
LANGUAGE: Chinese  
OTHER SOURCE(S): CASREACT 141:90826  
IT 27152-62-1P,  $\beta$ -(Methylamino)propiophenone  
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation);  
RACT (Reactant or reagent)  
(preparation and reduction of)  
RN 27152-62-1 HCAPLUS  
CN 1-Propanone, 3-(methylamino)-1-phenyl- (9CI) (CA INDEX NAME)



L21 ANSWER 15 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
ED Entered STN: 14 Nov 2003  
GI



AB Title compds. I [X, Y = H, aryl, cyano, etc.; R1 = H, alkyl, alkenyl, etc.; R2, R3 = H, alkyl, hydroxalkylene (sic), etc.], their diastereomers and pharmaceutically acceptable salts were prepared. For example, condensation of 4-aminobenzamide, triethylorthoformate and thiazolidinone II, e.g., prepared from cyanoaetic acid Et ester in 2-steps, afforded a diastereomeric mixture of thiazolidinones III. In human polo-like kinase-1

(PLK-1) inhibition assays, 29-examples of compds. I exhibited IC50 values ranging from 100-6300 nM, e.g., the IC50 value of thiazolidinones III was 200 nM.

ACCESSION NUMBER: 2003:892761 HCAPLUS

DOCUMENT NUMBER: 139:381496

TITLE: Preparation of (4-oxo-2-thiazolidinylidene)acetonitrile and related compounds as polo-like kinase-1 (PLK-1) inhibitors

INVENTOR(S): Schwede, Wolfgang; Schulze, Volker; Eis, Knut; Buchmann, Bernd; Briem, Hans; Simeister, Gerhard; Boemer, Ulf; Parczyk, Karsten

PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 252 pp.

CODEN: PIIXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003093249	A1	20031113	WO 2003-EP4450	20030429

Young, Shawquia, Page 9


L21 ANSWER 15 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TV, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG  
CA 2484597 AA 20031113 CA 2003-2484597 20030429  
AU 2003222845 A1 20031117 AU 2003-222845 20030429  
EP 1501794 A1 20050202 EP 2003-718796 20030429  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
BR 2003009758 A 20050215 BR 2003-9758 20030429  
CN 1649853 A 20050803 CN 2003-810042 20030429  
JP 2005538048 T2 20051215 JP 2004-501388 20030429  
NO 2004005281 A 20050201 NO 2004-5281 20041202  
US 2006079503 A1 20060413 US 2005-513368 20050810  
PRIORITY APPLN. INFO.: DE 2002-10221104 A 20020503  
WO 2003-EP4450 W 20030429

OTHER SOURCE(S): MARPAT 139:381496  
IT 623558-84-9P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(intermediate; preparation of thiazolidinones as polo-like kinase-1 (PLK-1) inhibitors)  
RN 623558-84-9 HCAPLUS  
CN Benzenepropanethioamide,  $\alpha$ -cyano-N-ethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L21 ANSWER 16 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 19 Sep 2003  
 GI



**AB** The present invention relates to amino(monocyclic aryl)pyridinones (shown as I; variables defined below; e.g. 5-benzoyl-1-(2-methoxyethyl)-6-[(2-methoxyethyl)amino]-2(1H)-pyridinone), processes for their preparation, and their use in medicaments, especially for the treatment of COPD and asthma. IC50 values are tabulated for inhibition of p38 map kinase by 8 examples of I, e.g. 0.202  $\mu$ M for 6-amino-5-benzoyl-1-phenyl-2(1H)-pyridinone. For I: R1 = H, C1-C8-alkyl, C6-C10-aryl heteroaryl, C3-C8-cycloalkyl or heterocyclyl, wherein C1-C8-alkyl, C6-C10-aryl, heteroaryl, heterocyclyl or C3-C8-cycloalkyl can be substituted with 0 to 3 substituents; R2 = H, amino, mono- or di-C6-alkylamino, C3-C8-cycloalkylamino, C6-C10-arylamino, C1-C8-alkyl, heteroaryl, C3-C8-cycloalkyl or heterocyclyl, wherein mono- or di-C6-alkylamino, C3-C8-cycloalkylamino, C6-C10-arylamino, C1-C8-alkyl, C6-C10-aryl, heteroaryl, heterocyclyl or C3-C8-cycloalkyl can be substituted with 0 to 3 substituents. R3 = H or C1-C6-alkyl; R4 = -COR1-, wherein R4-1 = C6-C10-aryl or heteroaryl; with the proviso that R1, R2 and R3 are not H at the same time; addnl. details are given in the claims. More than 100 example preps. and/or characterization data of intermediates and 155 of

I are included. For example, 5-benzoyl-1-(2-methoxyethyl)-6-[(2-methoxyethyl)amino]-2(1H)-pyridinone (22 %) was prepared from 3,3-bis[(2-methoxyethyl)amino]-1-phenyl-2-propen-1-one (0.61 mmol), propionic acid (0.92 mmol) and 1-[(1H-imidazol-1-yl)carbonyl]-1H-imidazole (1.10 mmol).  
**ACCESSION NUMBER:** 2003:737727 HCAPLUS  
**DOCUMENT NUMBER:** 139:261170  
**TITLE:** Preparation of amino(monocyclic aryl)pyridinones that inhibit p38 map kinase for use as antiinflammatory agents  
**INVENTOR(S):** Alonso-Aluja, Cristina; Michels, Martin; Schirok, Hartmut; Schlemmer, Karl-Heinz; Bell, John; Fitzgerald, Mary F.; Dodd, Sara; Gill, Andrew  
**PATENT ASSIGNEE(S):** Bayer Aktiengesellschaft, Germany  
**SOURCE:** PCT Int. Appl., 198 pp.  
**CODEN:** PIXXD2  
**DOCUMENT TYPE:** Patent  
**LANGUAGE:** English

L21 ANSWER 17 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 28 May 2003  
**AB** Mixts. of 3-benzoylated and 3-unsubstituted 6-hydroxypiperidine-2-thione deriva. were formed in the reaction of benzoyl(acetyl) thioacetamides with  $\alpha,\beta$ -unsatd. aldehydes in refluxing ethanol in the presence of catalytic amts. of triethylamine. A mechanism for the debenzylation was proposed. Deriva. of 6H-thiopyran were obtained when an analogous reaction was carried out in refluxing pyridine. The structures of all compds. were determined with the aid of 1D NMR (1H, 13C, 13C-DEPT-135) and 2D NMR (1H, 1H COSY, 1H, 1H NOESY, 13C, 1H COSY) spectroscopy.  
**ACCESSION NUMBER:** 2003:406299 HCAPLUS  
**DOCUMENT NUMBER:** 139:230588  
**TITLE:** Reactions of  $\beta$ -keto thioamides with  $\alpha,\beta$ -unsaturated aldehydes. Synthesis of 6-hydroxypiperidine-2-thiones and 6H-thiopyrans  
**AUTHOR(S):** Jagodzinski, Tadeusz S.; Somiczki, Jacek G.; Wesolowska, Aneta  
**CORPORATE SOURCE:** Department of Organic Chemistry, Technical University of Szczecin, Szczecin, PL-71065, Pol.  
**SOURCE:** Tetrahedron (2003), 59(23), 4183-4192  
**PUBLISHER:** Elsevier Science,Ltd.  
**DOCUMENT TYPE:** Journal  
**LANGUAGE:** English  
**OTHER SOURCE(S):** CASREACT 139:230588  
**IT** 56617-74-4 56617-75-5  
**RL:** RCT (Reactant); RACT (Reactant or reagent)  
 (reactions of  $\beta$ -keto thioamides with  $\alpha,\beta$ -unsatd. aldehydes)  
**RN** 56617-74-4 HCAPLUS  
**CN** Benzenepropanethioamide, N-methyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)



RN 56617-75-5 HCAPLUS.  
 CN Benzenepropanethioamide, N-ethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)




**REFERENCE COUNT:** 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L21 ANSWER 16 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003076405	A1	20030918	WO 2003-EP2154	20030303
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MM, MW, SD, SL, SZ, TZ, UG, ZM, ZW				
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
CA 2478936	AA	20030918	CA 2003-2478936	20030303
AU 2003223953	A1	20030922	AU 2003-223953	20030303
EP 1487794	A1	20041222	EP 2003-720315	20030303
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 200308429	A	20050111	BR 2003-8429	20030303
CN 1653047	A	20050810	CN 2003-810486	20030303
JP 2005526068	T2	20050902	JP 2003-574626	20030303
ZA 2004007211	A	20050909	ZA 2004-7211	20040909
US 2006046999	A1	20060302	US 2005-507754	20050523
PRIORITY APPLN. INFO.:			GB 2002-6019	A 20020314
			GB 2002-21951	A 20020920
			GB 2002-27431	A 20021125
			WO 2003-EP2154	W 20030303

OTHER SOURCE(S): MARPAT 139:261170  
 IT 56617-74-4, N-Methyl-3-oxo-3-phenylpropanethioamide  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of amino(monocyclic aryl)pyridinones that inhibit p38 map kinase for use as antiinflammatory agents)

RN 56617-74-4 HCAPLUS  
 CN Benzenepropanethioamide, N-methyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L21 ANSWER 18 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 29 Oct 2002  
**AB** In the search for new active bis- $\beta$ -aminoketones, a series of compds. was synthesized by aminomethylation of *p*-substituted 1,6-bisaryl-1,6-hexanediones and 1,8-bisaryl-1,8-octanediones with ethylamine or tert-butylamine. The 1,6-bisaryl-2,5-bis(aminomethyl)-1,6-hexanedione dihydrochlorides are stable crystalline substances, whereas many of the 1,8-bisaryl-2,7-bis(aminomethyl)-1,8-octanedione dihydrochlorides are hygroscopic. The 1,6-bisaryl-2,5-bis(aminomethyl)-1,6-hexanedione dihydrochlorides administered in a dose of 10 mg/kg exhibited neither analgesic nor antiinflammatory activity. All compds. introduced intracutaneously in the form of 2% solns. produced pronounced local irritant action. Most of the 1,6-bisaryl-2,5-bis(aminomethyl)-1,6-hexanedione dihydrochlorides showed local anesthetic activity according to the conduction anesthesia test, but had no effect in the surface anesthesia test.  
**ACCESSION NUMBER:** 2002:822385 HCAPLUS  
**DOCUMENT NUMBER:** 139:25218  
**TITLE:** Synthesis and pharmacological activity of 1,6-bisaryl-2,5-bis(aminomethyl)-1,6-hexanedione dihydrochlorides. Synthesis of 1,8-bisaryl-2,7-bis(aminomethyl)-1,8-octanedione dihydrochlorides Agababyan, A. G.; Gevorgyan, G. A.; Sarkisyan, Dz. S.; Tumadzhyan, A. E.  
**CORPORATE SOURCE:** Mndzoyan Institute of Fine Organic Chemistry, National Academy of Sciences of Armenia, Yerevan, Armenia  
**SOURCE:** Pharmaceutical Chemistry Journal (Translation of Khimiko-Farmatsevticheskii Zhurnal) (2002), 36(6), 292-294  
**PUBLISHER:** PCJOAU; ISSN: 0091-150X  
**DOCUMENT TYPE:** Journal  
**LANGUAGE:** English  
**IT** 560120-18-5P 560120-19-6P 560120-20-9P  
**RL:** ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (synthesis and pharmacol. activity of aryl(aminomethyl)hexanediones and synthesis of aryl(aminomethyl)octanediones in relation to local anesthetic activity and toxicity)  
**RN** 560120-18-5 HCAPLUS  
**CN** 1,6-Hexanedione, 2,5-bis[(ethylamino)methyl]-1,6-bis(4-methoxyphenyl)- dihydrochloride (9CI) (CA INDEX NAME)

L21 ANSWER 18 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN


(Continued)



●2 HCl

RN 560120-19-6 HCAPLUS


CN 1,6-Hexanedione, 2,5-bis(4-ethoxyphenyl)-2,5-bis[(ethylamino)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 560120-20-9 HCAPLUS

CN 1,6-Hexanedione, 2,5-bis[(ethylamino)methyl]-1,6-bis(4-propoxyphe- nyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 560120-21-0 HCAPLUS

CN 1,6-Hexanedione, 1,6-bis(4-butoxyphenyl)-2,5-bis[(ethylamino)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

L21 ANSWER 18 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


IT 560120-29-8P 560120-30-1P 560120-31-2P

560120-32-3P 560120-33-4P 560120-34-5P

RL: SPN (Synthetic preparation); PREP (Preparation) (synthesis and pharmacol. activity of aryl(aminomethyl)hexanediones and synthesis of aryl(aminomethyl)octanediones in relation to local anesthetic activity and toxicity)

RN 560120-29-8 HCAPLUS


CN 1,8-Octanedione, 2,7-bis[(ethylamino)methyl]-1,8-diphenyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 560120-30-1 HCAPLUS


CN 1,8-Octanedione, 2,7-bis[(ethylamino)methyl]-1,8-bis(4-methoxyphenyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 560120-31-2 HCAPLUS

CN 1,8-Octanedione, 1,8-bis(4-ethoxyphenyl)-2,7-bis[(ethylamino)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 560120-32-3 HCAPLUS

CN 1,8-Octanedione, 2,7-bis[(ethylamino)methyl]-1,8-bis(4-propoxyphe- nyl)-,

Young, Shawquia, Page 11

L21 ANSWER 18 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



●2 HCl


IT 560120-17-4P 560120-22-1P

RL: ADV (Adverse effect, including toxicity); SPN (Synthetic preparation);

BIOI (Biological study); PREP (Preparation) (synthesis and pharmacol. activity of aryl(aminomethyl)hexanediones and synthesis of aryl(aminomethyl)octanediones in relation to local anesthetic activity and toxicity)

RN 560120-17-4 HCAPLUS


CN 1,6-Hexanedione, 2,5-bis[(ethylamino)methyl]-1,6-diphenyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 560120-22-1 HCAPLUS


CN 1,6-Hexanedione, 2,5-bis[(ethylamino)methyl]-1,6-bis(4-(pentyloxy)phenyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L21 ANSWER 18 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 560120-33-4 HCAPLUS


CN 1,8-Octanedione, 1,8-bis(4-butoxyphenyl)-2,7-bis[(ethylamino)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 560120-34-5 HCAPLUS

CN 1,8-Octanedione, 2,7-bis[(ethylamino)methyl]-1,8-bis(4-(pentyloxy)phenyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

REFERENCE COUNT:

9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L21 ANSWER 19 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 12 Jul 2002  
 G1

## \* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB The invention relates to a new multi-step process for preparing  $(\pm)$ -trans-4-p-fluorophenyl-3-hydroxymethyl-1-methylpiperidine ( $(\pm)$ -I), an important intermediate in the preparation of the well-known antidepressants paroxetine and omiloxetine. The invention also relates to: (1) various novel intermediates formed in the new preparation of ( $\pm$ -I); (2) methods for preparing, these new intermediates, and (3) the use of either the new intermediates or derived ( $\pm$ -I) for preparing paroxetine or omiloxetine. The new method avoids a host of specific problems which occur in several existing methods of preparing ( $\pm$ -I). In particular, 3 functional groups are simultaneously reduced, providing the desired trans stereocenter, in I directly, and avoiding the need for further epimerization.

Steps. For instance, Mannich reaction of p-fluoracetophenone with Ph-CH<sub>2</sub>NHMe-HCl and paraformaldehyde gave 84% of novel intermediate II-HCl. Hydrogenolytic debenzylating of the latter (96%) and amidation of the resultant novel secondary amine with ClCOCH<sub>2</sub>CO<sub>2</sub>Me (88%) gave the new intermediate ester III. Base-catalyzed cyclization of III using MeONa in MeOH gave, depending upon conditions, pyridinone IV (82%) or a 1:1 mixture of IV and its double-bond isomer V (90%). Reduction of IV and/or V using, e.g., LiAlH<sub>4</sub> in THF, gave ( $\pm$ -I) without contamination by epimers, in good (65%) yield.

ACCESSION NUMBER: 2002:521706 HCAPLUS  
 DOCUMENT NUMBER: 137:78863  
 TITLE: Novel process for preparing  $(\pm)$ -trans-4-(p-fluorophenyl)-3-(hydroxymethyl)-1-methylpiperidine, an intermediate for paroxetine and omiloxetine.  
 INVENTOR(S): Peque, Rafael; Rementol, Jorge; Petachen, Ines; Salares, Juan; Campa, Francesc X.; Raga, Manuel M.; Castello, Josep M.; Armengol, Miguel P.; Fernandez-Cano, Diego  
 PATENT ASSIGNEE(S): Ferret Internacional S.A., Spain  
 SOURCE: PCT Int. Appl. 32 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053537	A1	20020711	WO 2001-EP49	20010104
WO 2002053537	C1	20020808		

L21 ANSWER 19 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 19 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 W: AU, BR, CA, IL, JP, KR, MX, NO, NZ, US, ZA  
 RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR  
 CA 2433605 AA 20020711 CA 2001-2433605 20010104  
 EP 1347960 A1 20031001 EP 2001-901146 20010104  
 EP 1347960 B1 20041117  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR  
 BR 2001016721 A 20031223 BR 2001-16721 20010104  
 JP 2004520333 T2 20040708 JP 2002-554656 20010104  
 AT 282594 E 20041215 AT 2001-901146 20010104  
 PT 1347960 T 20050331 PT 2001-901146 20010104  
 ES 2232588 T3 20050601 ES 2001-1901146 20010104  
 NZ 526874 A 20050729 NZ 2001-526874 20010104  
 TW 593279 B 20040621 TW 2001-90104450 20010227  
 NO 2003003049 A 20030818 NO 2003-3049 20030703  
 ZA 2003005207 A 20040705 ZA 2003-5207 20030704  
 US 2004215020 A1 20041028 US 2003-250519 20030915  
 US 6881845 B2 20050419  
 PRIORITY APPLN. INFO.: EP 2001-901146 A 20010104  
 WO 2001-EP49 W 20010104

OTHER SOURCE(S): CASREACT 137:78863; MARPAT 137:78863  
 IT 440673-07-4P, 1-(p-Fluorophenyl)-3-(methylamino)propan-1-one hydrochloride 440673-11-0P, 1-(p-Fluorophenyl)-3-(methylamino)propan-1-one  
 RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic Preparation); PREP (Preparation); RACT (Reactant or reagent) (process intermediate; improved preparation of (fluorophenyl)(hydroxymethyl)methylpiperidine as intermediate for paroxetine and omiloxetine)  
 RN 440673-07-4 HCAPLUS  
 CN 1-Propanone, 1-(4-fluorophenyl)-3-(methylamino)-, hydrochloride (9CI) (CA INDEX NAME)

INDEX NAME




● HCl

RN 440673-11-0 HCAPLUS  
 CN 1-Propanone, 1-(4-fluorophenyl)-3-(methylamino)- (9CI) (CA INDEX NAME)

L21 ANSWER 20 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 16 Apr 2002  
 AB A general scheme was developed for the cascade and stage oxidation of 1,4-disubstituted 1,2,3,6-tetrahydropyridines by potassium permanganate, based on the successive oxidation of the allylic triad of carbon atoms in the piperidine ring. In the case of 4-aryltetrahydropyridines 2-oxotetrahydropyridines are formed initially. 3,4-Dihydroxypiperidin-2-ones and finally 1-aminoalkan-3-one are then formed. The oxidation of 4-methyl-substituted tetrahydropyridines to the analogous 1-aminoalkanones begins differently - with 3,4-dihydroxylation followed by lactamization of the piperidinediol.


ACCESSION NUMBER: 2002:283018 HCAPLUS  
 DOCUMENT NUMBER: 137:78622  
 TITLE: Oxidative reactions of azines. 9. Cascade and stage oxidation of 1,4-disubstituted 1,2,3,6-tetrahydropyridines by potassium permanganate  
 AUTHOR(S): Soldatenkov, A. T.; Temesgen, A. V.; Bekro, I. A.  
 CORPORATE SOURCE: Russian Peoples Friendship University, Moscow,  
 117193, Russia  
 SOURCE: Chemistry of Heterocyclic Compounds (New York, NY, United States) (Translation of Khimya Geterotsiklicheskikh Soedinenii) (2001), 37(10), 1216-1222  
 CODEN: CHCCAL; ISSN: 0009-3122  
 PUBLISHER: Kluwer Academic/Consultants Bureau  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 137:78622  
 IT 27152-62-1 RL: SPN (Synthetic preparation); PREP (Preparation) (cascade and stage oxidation of 1,4-disubstituted 1,2,3,6-tetrahydropyridines by potassium permanganate)  
 RN 27152-62-1 HCAPLUS  
 CN 1-Propanone, 3-(methylamino)-1-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

26/12/2006, 10525820e.trn

L21 ANSWER 21 OF 137 HCPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 04 Jan 2002  
 GI



AB The title compds. [I; E = a bond; C(R4)2; R1, R2 = H, alkyl; R3 = H, alkyl, cycloalkyl, etc.; R4, R5 = H, alkyl], for inhibiting MRP1 in a mammal [no data], were prepared. E.g., a multi-step synthesis of I [E = CH2];

R1-R2 = H; R3 = Ph; R5 = H was given.

ACCESSION NUMBER: 2002:10444 HCPLUS

DOCUMENT NUMBER: 136:69745

TITLE: Preparation of quinoline-2,4-diones for inhibiting MRP1

INVENTOR(S): Bonjouklian, Rosanne; York, Jeremy Schulenburg

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 35 pp.

CODEN: PIIXDZ

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200200624	A2	20020103	WO 2001-US10849	20010612
WO 200200624	A3	20020418		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2413579	AA	20020103	CA 2001-2413579	20010612
AU 2001068040	AS	20020108	AU 2001-68040	20010612
EP 1296953	A2	20030402	EP 2001-945932	20010612
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003232854	A1	20031218	US 2002-297275	20021204
US 6686376	B2	20040203		
PRIORITY APPLN. INFO.:		US 2000-213380P		P 20000623


L21 ANSWER 21 OF 137 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 ED Entered STN: WO 2001-US10849 W 20010612

OTHER SOURCE(S): MARPAT 136:69745


IT 384850-10-6P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of quinoline-2,4-diones for inhibiting MRP1)

RN 384850-10-6 HCPLUS

CN 2-Pentenoic acid, 5-(2-chloro-6-fluorophenyl)-3-(methylamino)-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)



L21 ANSWER 22 OF 137 HCPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 10 Aug 2001  
 GI



AB The title compds. I (R1 and R2 are each hydrogen, nitro, cyano, halogeno, Cl-6 alkyl, Cl-6 alkylsulfonyl, or the like; R3 is nitro, cyano, halogeno,

halogeno, Cl-6 alkyl, or the like; n is 0, 1 or 2; R4 and R5 are each hydrogen, Cl-6

alkyl, Cl-6 alkoxy, or the like, or alternatively they may be united to form an alkylene chain, a heterocyclic group, or the like; X is oxygen or sulfur; and Z is formyl, di(Cl-6 alkoxy)methyl, Ph, a heterocyclic group, or the like) are prepared

3-(Azetidin-1-yl)-2-[2-methyl-3-(3-methoxyisoxazol-

-5-yl)-4-(methylsulfonyl)phenyl]-3-oxopropanenitrile at 250 g/have given 80%

to 89% control of Abutilon avicinnae.

ACCESSION NUMBER: 2001:581835 HCPLUS

DOCUMENT NUMBER: 135:152794

TITLE: Preparation of substituted cyanoacetamide derivatives as herbicides

INVENTOR(S): Yamamoto, Hiroyuki; Kajita, Satoshi; Tanaka, Kataunori; Koguchi, Masami; Yamada, Shigeo;

Takahashi,

Akihiro

PATENT ASSIGNEE(S): Nippon Soda Co., Ltd, Japan

SOURCE: PCT Int. Appl., 54 pp.

CODEN: PIIXDZ

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001056979	A1	20010809	WO 2001-JP603	20010130
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:		JP 2000-27226		A 20000131
		JP 2000-304838		A 20001004

L21 ANSWER 22 OF 137 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 OTHER SOURCE(S): MARPAT 135:152794

IT 353236-70-1P  
 RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of substituted cyanoacetamide derive. as herbicides)


RN 353236-70-1 HCPLUS

CN Benzenepropanamide,  $\alpha$ -cyano-N,2-dimethyl-3-(3-methyl-5-isoxazolyl)-4-(methylsulfonyl)-3-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L21 ANSWER 23 OF 137 HCPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 13 Jul 2001  
 GI



**AB** The invention relates to piperidine-substituted  $\alpha$ - or  $\beta$ -amino acids (I); R = (un)saturated (un)substituted heterocycle; R1 = Ph, naphthyl, (un)substituted heterocycle; R2 = H, alkyl; A, Al1 = H; when one of A or Al1 = H, the other = NH2, 1,4'-bipiperidyl, alkylamino, N(R3)(Z-R4)(forming (substituted)  $\alpha$ - or  $\beta$ -amino acid); R3 = H, alkyl; Z = C(O), SO2; R4 = alkoxy, amino, (di)alkylamino, substituted heterocycle) their tautomers, diastereomers, enantiomers, mixtures, and to their salts, in particular, their physiol. compatible salts, with inorg. or organic acids or bases, which comprise valuable pharmacol. properties, in particular, CGRP-antagonistic properties. The invention also relates to medicaments containing these compds., to their use and to methods for the production thereof; formulations were given. Preparation of fragments CO2HC(R2)AC(O)R1, and

A or Al1 substituents were given. Thus (R,S)-4-(4-amino-3,5-dibromophenyl)-2-((1,1-dimethylethoxy carbonyl)methylamino)-4-oxo-butanoic acid was reacted with 3-(piperidinyl)-1,3,4,5-tetrahydro-1,3-benzodiazepin-2(2H)-one to give I (R = 1,3,4,5-tetrahydro-1,3-benzodiazepin-2(2H)-one; R1 = 4-amino-3,5-dibromophenyl; R2 = H; A = (1,1-dimethylethoxy carbonyl)methylamino; Al1 = H). In *in vitro* tests using SK-N-MC cells as tests of human CGRP-receptor binding affinity, I had IC50 <10000 nM, and acted as CGRP antagonists at doses between 10-11 - 10-5 M.

ACCESSION NUMBER: 2001:507689 HCPLUS

DOCUMENT NUMBER: 135:92860

TITLE: Preparation of piperidine-substituted amino-acids for use in treatment of CGRP-mediated disorders

INVENTOR(S): Rudolf, Klaus; Eberlein, Wolfgang; Dreyer, Alexander;

Muller, Stephan Georg; Doods, Henri; Bauer, Eckhart

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany

SOURCE: PCT Int. Appl., 153 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----

L21 ANSWER 23 OF 137 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L21 ANSWER 23 OF 137 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 WO 2001049676 A1 20010712 WO 2000-EP13236 200001222  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GA, GN, GW, ML, MR, NE, SN, TD, TG, BE, DK, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 DE 19963868 A1 20010712 DE 1999-19963868 19991230  
 CA 2395541 AA 20010712 CA 2000-2395541 20001222  
 BR 2000017063 A 20021022 BR 2000-17063 20001222  
 EP 1252153 A1 20021030 EP 2000-991806 20001222  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 HU 200300002 A2 20030548 HU 2003-2 20001222  
 JP 2003519222 T2 20030617 JP 2001-550216 20001222  
 EE 200200369 A 20031015 EE 2002-369 20001222  
 AU 783275 B2 20051006 AU 2001-35379 20001222  
 NZ 519939 A 20060831 NZ 2000-519939 20001222  
 BG 106848 A 20021229 BG 2002-106848 20020620  
 ZA 2002005181 A 20030930 ZA 2002-5181 20020627  
 NO 2002003161 A 20020628 NO 2002-3161 20020628  
 US 2003012057 A1 20031113 US 2002-169009 20021107  
 US 6949541 B2 20050927 US 2002-169009 20021107  
 HK 1054026 A1 20050916 HK 2003-106237 20030901  
 PRIORITY APPLN. INFO.: DE 1999-19963868 A 19991230  
 WO 2000-EP13236 W 20001222

OTHER SOURCE(S): MARPAT 135:92860

IT 349534-94-7 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of piperidine-substituted amino-acids for use in treatment of CGRP-mediated disorders)


RN 349534-94-7 HCPLUS

CN Piperazine, 1-[4-(4-amino-3,5-dibromophenyl)-2-(methylamino)-1,4-dioxobetyl]-1-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS

L21 ANSWER 24 OF 137 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 ED Entered STN: 26 Jan 2001  
 GI



**AB** Title compds. [I: R = H, OH, bond; R1, R2 = H, alkyl, aryl, aralkyl; R3 = H, OH, NH2, halo, alkyl, alkenyl, aryl, aralkyl, OR7, etc.; R4-R6 = H, OH, cyano, halo, alkyl, aryl, heterocyclyl; aralkyl, heterocyclylalkyl, OR7, SR7, etc.; R7 = alkyl, aryl, aralkyl; R12 = H, alkyl, cycloalkyl, aryl, aralkyl], were prepared. Thus, 1-(3-methoxyphenyl)-3-phenylpropan-1-one (preparation given) was heated with paraformaldehyde iminium salt and dimethylamine hydrochloride in MeCN at 60° to give 83% 2-benzyl-3-dimethylamino-1-(3-methoxyphenyl)propan-1-one hydrochloride. Tested I at 10 mg/kg i.v. in mice gave 62-100% inhibition of phenylquinone-induced writhing.

ACCESSION NUMBER: 2001:63953 HCPLUS

DOCUMENT NUMBER: 134:131314

TITLE: Preparation of 3-amino-2-benzyl-1-phenylpropanes as drugs.

INVENTOR(S): Sattlegger, Michael; Buschmann, Helmut; Koegel, Babette-Yvonne

PATENT ASSIGNEE(S): Grunenthal G.m.b.H., Germany

SOURCE: PCT Int. Appl., 124 pp.

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001005743 A1 20010125 WO 2000-EP5820 20000623	-----	-----	-----	-----
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ZA, PT, SE	-----	-----	-----	-----
DE 19933421 A1 20010125 DE 1999-19933421 19990716	-----	-----	-----	-----
CA 2378723 AA 20010125 CA 2000-2378723 20000623	-----	-----	-----	-----
EP 1196373 A1 20020417 EP 2000-943873 20000623	-----	-----	-----	-----


26/12/2006, 105258.20e.trn

L21 ANSWER 24 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO  
 BR 2000012622 A 20020611 BR 2000-12623 20000623  
 HU 200201797 A2 20021228 HU 2002-1797 20000623  
 JP 2003505358 T2 20030212 JP 2001-511404 20000623  
 NZ 517164 A 20040227 NZ 2000-517164 20000623  
 AU 78632 B2 20041216 AU 2000-58189 20000623  
 NO 2002000212 A 20020115 NO 2002-212 20020115  
 US 2002161262 A1 20021031 US 2002-46567 20020116  
 US 6653508 B2 20031125 20020214  
 ZA 2002001276 A 20030514 ZA 2002-1276 20020214  
 DE 1999-19933421 A 19990716  
 PRIORITY APPLN. INFO.:  
 WO 2000-EP5820 W 20000623

OTHER SOURCE(S): MARPAT 134:131314  
 IT 321749-42-2P 321749-43-3P 321749-48-8P  
 321749-49-9P 321749-50-2P 321749-51-3P  
 RL: BAC (Biological activity or effector, except adverse); BSU  
 (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
 BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of 3-amino-2-benzyl-1-phenylpropanes as drugs)  
 RN 321749-42-2 HCAPLUS  
 CN 1-Propanone, 1-(3-methoxyphenyl)-2-((methylamino)methyl)-3-(2-methylphenyl)-, hydrochloride (9CI) (CA INDEX NAME)




RN 321749-43-3 HCAPLUS  
 CN 1-Propanone, 1-(3-methoxyphenyl)-2-((methylamino)methyl)-3-(2-methylphenyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 321749-48-8 HCAPLUS  
 CN 1-Propanone, 3-(3-fluorophenyl)-1-(3-methoxyphenyl)-2-

L21 ANSWER 24 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 ((methylamino)methyl)- (9CI) (CA INDEX NAME)




RN 321749-49-9 HCAPLUS  
 CN 1-Propanone, 3-(3-fluorophenyl)-1-(3-methoxyphenyl)-2-((methylamino)methyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 321749-50-2 HCAPLUS  
 CN 1-Propanone, 3-(3-fluorophenyl)-1-(3-hydroxyphenyl)-2-((methylamino)methyl)- (9CI) (CA INDEX NAME)



RN 321749-51-3 HCAPLUS  
 CN 1-Propanone, 3-(3-fluorophenyl)-1-(3-hydroxyphenyl)-2-((methylamino)methyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 24 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


L21 ANSWER 25 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 29 Sep 2000  
 AB Fluoxetine-HCl was prepared by seven different synthetic routes, all previously reported. The major impurities in each route were identified by GC/MS, HPLC/MS, and gradient HPLC anal. Impurities were classified as being derived from impurities in 4-chlorobenzotrifluoride, those arising during the SNAr reaction of this compound and 3-methylamino-1-phenylpropanol, and those arising during the synthesis of this alc. Fifteen impurities belonging to the latter two categories were identified, and their structures were confirmed by synthesis of authentic material for most of the compds. It was found that a variety of anal. tools was needed for complete characterization of the impurity profile of fluoxetine HCl and that purification of the intermediate and recrystn. of the drug itself are highly effective in minimizing the levels of the impurities.  
 ACCESSION NUMBER: 2000:683252 HCAPLUS  
 DOCUMENT NUMBER: 134:21369  
 TITLE: Identification and Comparison of Impurities in Fluoxetine Hydrochloride Synthesized by Seven Different Routes  
 AUTHOR(S): Wirth, David D.; Miller, Marybeth S.; Boini, Sathish K.; Koenig, Thomas M.  
 CORPORATE SOURCE: Lilly Research Laboratories, Eli Lilly and Co., Lafayette, IN, 47909-9201, USA  
 SOURCE: Organic Process Research & Development (2000), 4(6), S13-S19  
 PUBLISHER: CODEN: OPRDPK; ISSN: 1083-6160  
 DOCUMENT TYPE: American Chemical Society  
 LANGUAGE: Journal  
 English  
 IT 27152-62-1P  
 RL: BYP (Byproduct); PREP (Preparation)  
 (impurities in fluoxetine hydrochloride synthesized by seven different routes)  
 RN 27152-62-1 HCAPLUS  
 CN 1-Propanone, 3-(methylamino)-1-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


26/12/2006, 10525820e.trn

L21 ANSWER 26 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 14 Aug 2000  
 AB 4-Morpholinocoumarin was obtained in the reaction of 4-(2-hydroxychalconoyl)morpholine with Et bromoacetate in the presence of PPh<sub>3</sub> and NEt<sub>3</sub>. Analogous reactions of 3-keto thioamides with Et bromoacetate and Et 2-bromopropionate, carried out in THF or acetone, yielded cyclic derivs. of N-substituted 2-acylmethylidene-1,3-thiazolidin-4-ones. In the reaction with Et 3-bromopropionate only S-alkylation of the thioamide was observed. The reaction of the indandione-derived thioamides with Et bromoacetate in acetone gave the condensation products of 2-acylmethylidene-1,3-thiazolidin-4-ones with acetone. 2-Acylmethylidene-1,3-thiazolidin-4-ones condensed with benzaldehyde to give the 5-benzylidene deriv.  
 ACCESSION NUMBER: 2000:558201 HCAPLUS  
 DOCUMENT NUMBER: 133:281742  
 TITLE: Reactions of secondary  $\beta$ -ketothioamides with ethyl bromoacetate and ethyl 2-bromopropionate. The synthesis of N-substituted 2-acylmethylidene-1,3-thiazolidin-4-ones  
 AUTHOR(S): Jagodzinski, T. S.; Wesolowska, A.; Soaniciki, J. G.  
 CORPORATE SOURCE: Department of Organic Chemistry, Technical University of Szczecin, Szczecin, 71-065, Pol.  
 SOURCE: Polish Journal of Chemistry (2000), 74(8), 1101-1114  
 PUBLISHER: Polish Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 133:281742  
 IT 56617-74-4  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (reactant for preparation of acylmethylidenethiazolidinones)  
 RN 56617-74-4 HCAPLUS  
 CN Benzenepropanethioamide, N-methyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 27 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 11 Aug 2000  
 AB The carboxylic groups of horseradish peroxidase were modified by 1-cyclohexyl-3-(2-morpholinoethyl)carbodiimide metho-p-toluenesulfonate by the Koshland method. The catalytic properties of the native and modified peroxidase were studied in the presence of N-ethylamide of o-sulfonylbenzoic acid (EASBA) at pH 5.0-7.5. In the oxidation of o-dianisidine, EASBA is a competitive inhibitor of the carbodiimide-modified peroxidase, and it increases both Km and Vm in the case of the native enzyme. These data show that at least one of the carboxylic groups modified with carbodiimide is located at the area of the peroxidase active site.  
 ACCESSION NUMBER: 2000:552386 HCAPLUS  
 DOCUMENT NUMBER: 133:292793  
 TITLE: Inhibition of horseradish peroxidase by N-ethylamide of o-sulfonylbenzoic acid  
 AUTHOR(S): Rogozhin, V. V.; Kutuzova, G. D.; Ugarova, N. N.  
 CORPORATE SOURCE: Yakutsk State Agricultural Academy, Yakutsk, 677002, Russia  
 SOURCE: Russian Journal of Bioorganic Chemistry (Translation of Bioorganicheskaya Khimiya) (2000), 26(2), 138-141  
 PUBLISHER: MAIK Nauka/Interperiodica  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 103383-39-7  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
 (inhibition of horseradish peroxidase by N-ethylamide of sulfonylbenzoic acid)  
 RN 103383-39-7 HCAPLUS  
 CN Benzenesulfonic acid, 3-(3-(ethylamino)-1,3-dioxopropyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 28 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 27 Dec 1999  
 GI




AB Water is supplied to an exposed photosensitive material using a spray or an elastic porous substance impregnated with water, wherein the photosensitive material contains photosensitive Ag halide, a binder, anilide I (R1, R4 = H, substituent; A = OH, amino; X = CO, SO, SO<sub>2</sub>, PO; Y = divalent group; Z = nucleophilic group), and a compound forming a diffusible pigment by reaction with oxidized I. The method prevents dissolution of the chems. of the material into H<sub>2</sub>O. The diagram of the water supplying appr. are given.

ACCESSION NUMBER: 1999:814652 HCAPLUS  
 DOCUMENT NUMBER: 132:71429  
 TITLE: Image formation using heat development photosensitive material  
 INVENTOR(S): Taguchi, Keiichi  
 PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 72 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
JP 11352648	A2	19991224	JP 1998-172126	19980605
PRIORITY APPLN. INFO.:			JP 1998-172126	19980605

OTHER SOURCE(S): MARPAT 132:71429  
 IT 253178-14-2  
 RL: DEV (Device component use); USES (Uses)  
 (coupler; image formation using heat development photosensitive material)  
 RN 253178-14-2 HCAPLUS  
 CN Benzenepropanamide,  $\alpha$ -[3-[(4-(dodecyloxy)phenyl)sulfonyl]amino]phenoxyl-N-ethyl-4-[(methylsulfonyl)amino]- $\beta$ -oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 28 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




L21 ANSWER 29 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 18 Mar 1999  
 GI



AB Photocyclization of the heterocyclic 2,3-diones I ( $X = O, S, NH, NMe$ ) with electron rich alkenes affords regio- and stereoselectively the [2+2] adducts II ( $R = OAc, Ph, OEt$ ). From I ( $X = S$ ), with benzophenone as photosensitizer, the Paterno-Buchi adduct III was also obtained. Similarly, with phenylethyne the dihydroderivative of II ( $R = Ph$ ) were formed in moderate to low yields and, in case of I ( $X = NH$ ), an azepinone was the only product. Irradiation of I ( $X = NPh, 4-MeC6H4N$ ) with EtoCH<sub>2</sub>CH<sub>2</sub> gave the furo[3,2-c]pyrrolones IV ( $R = Ph, 4-MeC6H4$ ) via an unexpected 1,2-benzoyl migration. Structural elucidation of all ring systems is based on x-ray anal.


ACCESSION NUMBER: 1999:176586 HCAPLUS  
 DOCUMENT NUMBER: 130:325096  
 TITLE: Reactions of cyclic oxaryl compounds. 41. Regio- and stereoselective photocycloadditions of heterocyclic 2,3-diones - evidence for an unexpected 1,2-aroyl migration  
 AUTHOR(S): Kollenz, G.; Terpetachnig, E.; Sterk, H.; Peters, K.; Peters, E.M.  
 CORPORATE SOURCE: Institute for Organic Chemistry, Karl-Franzens University Graz, Graz, A-8010, Austria  
 SOURCE: Tetrahedron (1999), 55(10), 2973-2984  
 CODEN: TETRAB; ISSN: 0040-4020  
 PUBLISHER: Elsevier Science Ltd.  
 DOCUMENT TYPE: Journal

L21 ANSWER 30 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 29 Jun 1998  
 AB Asym. hydrogenation of PhCOCH<sub>2</sub>CONHMe under 200 psi of hydrogen pressure in the presence of a chiral BINAP-ruthenium(II) catalyst furnished (R)- or (S)-PhCH(OH)CH<sub>2</sub>CONHMe as the single enantiomer. The product can be used as an intermediate for chiral fluoxetine.  
 ACCESSION NUMBER: 1998:395523 HCAPLUS  
 DOCUMENT NUMBER: 129:135958  
 TITLE: The synthesis of a chiral fluoxetine intermediate by catalytic enantioselective hydrogenation of benzoylacetamide  
 AUTHOR(S): Huang, Hsiang-Ling; Liu, Lee Tai; Chen, Shyh-Fong; Ku,  
 CORPORATE SOURCE: Hao Development Center for Biotechnology, Taipei, Taiwan  
 SOURCE: Tetrahedron: Asymmetry (1998), 9(10), 1637-1640  
 CODEN: TASYE3; ISSN: 0957-4166  
 PUBLISHER: Elsevier Science Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 129:135958  
 IT 197852-01-0P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of a chiral fluoxetine intermediate by catalytic enantioselective hydrogenation of benzoylacetamide)  
 RN 197852-01-0 HCAPLUS  
 CN Benzene propanamide, N-methyl-β-oxo- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 29 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 LANGUAGE: English  
 IT 223916-45-8P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (regio- and stereoselective photocycloadditions of heterocycle diones and aroyl migration in photolysis of benzoylarylpyroledione)  
 RN 223916-45-8 HCAPLUS  
 CN 2-Butenamide, 3-benzoyl-2,4-dihydroxy-N-methyl-4-(methylamino)-4-phenyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 31 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 16 Jan 1998  
 AB Gradient HPLC and gas chromatog. were applied as screening methods for determination of impurities in fluoxetine HCl drug substances and formulated products from multiple sources. NMR spectroscopy was also used for identification of excipients and some residual solvents. Thirty potential impurities and excipients were investigated. Several impurities were observed in generic products using gradient HPLC that were not detected with isocratic pharmacopeial methods for fluoxetine HCl. Anal. of drug substance samples and capsule formulations from many different suppliers showed wide variation in quality which, in many cases, would go undetected using isocratic methods. The quality of the innovator's product and some generic samples was high, but many generic samples contained high levels of impurities. A new impurity, N-benzyl fluoxetine, was observed in some generic samples at levels as high as 0.9%. The gradient HPLC method was also used for stability studies and established that generic capsules formulated with lactose were less stable under accelerated conditions than those formulated without lactose.  
 ACCESSION NUMBER: 1998:26204 HCAPLUS  
 DOCUMENT NUMBER: 128:132529  
 TITLE: Screening methods for impurities in multi-sourced fluoxetine hydrochloride drug substances and formulations  
 AUTHOR(S): Wirth, D. D.; Olsen, B. A.; Hallenbeck, D. K.; Lake, M. E.; Gregg, S. M.; Perry, F. M.  
 CORPORATE SOURCE: Lilly Research Laboratories, Eli Lilly Co., Lafayette,  
 SOURCE: IN, 47902, USA  
 Chromatographia (1997), 46(9/10), 511-523  
 CODEN: CHRBGB; ISSN: 0009-5893  
 PUBLISHER: Friedrich Vieweg & Sohn Verlagsgesellschaft mbH  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 27152-62-1P  
 RL: ANT (Analyte); BYP (Byproduct); FMU (Formation, unclassified); ANST (Analytical study); FORM (Formation, nonpreparative); PREP (Preparation) (screening methods for impurities in fluoxetine HCl drug substances and formulations)  
 RN 27152-62-1 HCAPLUS  
 CN 1-Propanone, 3-(methylamino)-1-phenyl- (9CI) (CA INDEX NAME)




26/12/2006, 10525820e.trn

L21 ANSWER 32 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 30 Oct 1997  
 AB Incubation of the fungus Mortierella isabellina NRRL 1757 with  
 3-oxo-3-phenylpropanamide, 3-oxobutanimide, and with some of their  
 N-alkyl  
 deriva, afford the corresponding (S)-3-hydroxyamides, usually in high  
 chemical yields and enantiomeric excesses.  
 ACCESSION NUMBER: 1997:686178 HCAPLUS  
 DOCUMENT NUMBER: 127:330950  
 TITLE: Enantioselective reduction of  $\beta$ -keto amides by  
 the fungus Mortierella isabellina  
 AUTHOR(S): Quiros, Margarita; Rebollo, Francisca; Liz, Ramon;  
 Gotor, Vicente  
 CORPORATE SOURCE: Laboratorio de Quimica Biogenetica, Facultad de  
 Quimica, Universidad de Oviedo, Oviedo, 33071, Spain  
 SOURCE: Tetrahedron: Asymmetry (1997), 8(18), 3035-3038  
 CODEN: TASYB3; ISSN: 0957-4166  
 PUBLISHER: Elsevier  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 127:330950  
 IT 197852-01-0  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (enantioselective reduction of  $\beta$ -keto amides by the fungus  
 Mortierella  
 isabellina)  
 RN 197852-01-0 HCAPLUS  
 CN Benzene propanamide, N-methyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR  
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT


L21 ANSWER 33 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 30 Oct 1997  
 AB A thin layer chromatog. method to examine the related substances  
 ( $\omega$ -methylaminophenylpropanone, N-methyl-3-hydroxy-3-phenylpropane,  
 etc) from the synthetic process of fluoxetine hydrochloride was  
 established.  
 ACCESSION NUMBER: 1997:684913 HCAPLUS  
 DOCUMENT NUMBER: 127:283475  
 TITLE: TLC examination of related substances in fluoxetine  
 hydrochloride  
 AUTHOR(S): Gao, Damin; Wang, Aimin  
 CORPORATE SOURCE: Shanghai Institute of Pharmaceutical Industry,  
 Shanghai, 200437, Peop. Rep. China  
 SOURCE: Zhongguo Yiyao Gongye Zaishi (1997), 28(4), 175-177  
 PUBLISHER: ZYGEZA; ISSN: 1001-8255  
 DOCUMENT TYPE: Zhongguo Yiyao Gongye Zaishi Bianjibu  
 LANGUAGE: Chinese  
 IT 27152-62-1  
 RL: ANT (Analyte); ANST (Analytical study)  
 (determination of fluoxetine impurities by TLC)  
 RN 27152-62-1 HCAPLUS  
 CN 1-Propanone, 3-(methylamino)-1-phenyl- (9CI) (CA INDEX NAME)



L21 ANSWER 34 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 12 Jun 1997  
 AB The addition reaction of  $\omega$ -bromoacetophenone to aldimines RICH:NR2 (R1  
 = Ph, 2-ClC6H4, 4-O2NC6H4, 4-MeC6H4; R2 = Ph, 2-MeC6H4, Me,  
 n-Bu) by indium metal in THF-H2O gave  $\beta$ -amino ketones  
 R1CH(NHR2)CH2COPh.  
 ACCESSION NUMBER: 1997:366757 HCAPLUS  
 DOCUMENT NUMBER: 127:81201  
 TITLE: Indium-mediated addition of  $\omega$ -bromo ketone to  
 aldimines  
 AUTHOR(S): Sun, Pei Pei; Zhang, Yong Min  
 CORPORATE SOURCE: Department of Chemistry, Hangzhou University,  
 Hangzhou, 310028, Peop. Rep. China  
 SOURCE: Chinese Chemical Letters (1997), 8(4), 267-268  
 CODEN: CCLEE7  
 PUBLISHER: Chinese Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 24686-91-7P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (indium-mediated addition of  $\omega$ -bromoacetophenone to aldimines)  
 RN 24686-91-7 HCAPLUS  
 CN 1-Propanone, 3-(methylamino)-1,3-diphenyl- (9CI) (CA INDEX NAME)



L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 25 Sep 1996  
 GI



AB Drugs containing a  $\beta$ -oxo- $\beta$ -benzenepropane-thioamide derivative  
 represented by general formula (I; R1 and R2 represent each independently  
 Cl-6 alkyl, or R1 and R2 bind to each other to form C2-5 alkylene; R3 and  
 R4 represent each independently hydrogen, halogeno, Cl-6 alkyl, Cl-6  
 alkoxy, trifluoromethyl, cyano, nitro, C6-6 dialkylamino or imidazolyl,  
 optionally having one or more substituents selected from Cl-6 alkyl, Cl-6  
 alkoxy and halogeno) as the active ingredient are useful in the treatment  
 and prevention of kidney diseases, diseases caused by the proliferation

of smooth muscle fibers and heart diseases.  
 ACCESSION NUMBER: 1996:569661 HCAPLUS  
 DOCUMENT NUMBER: 125:212684  
 TITLE: Cardiovascular and renal agents containing  
 $\beta$ -oxo- $\beta$ -benzenepropanethioamide derivatives  
 INVENTOR(S): Beisho, Hideki; Abe, Youichi; Tamaki, Toshiaki;  
 Kimura, Shoji; Aki, Yasuharu; Mitsuoka, Masayoshi;  
 Nagae, Mieko; Seino, Asami; Narimatsu, Akihiro; Abe,  
 Yuji  
 PATENT ASSIGNEE(S): Mitsubishi Chemical Corporation, Japan  
 SOURCE: PCT Int. Appl.; 35 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
NO 9622086	A1	19960725	WO 1996-JP46	19960116
W: CA, JP, KR, US				
RN: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 07244393	A2	19950919	JP 1995-4949	19950117
PRIORITY APPLN. INFO.:			JP 1995-4747	A 19950117
			JP 1995-4748	A 19950117
			JP 1995-4949	A 19950117
			JP 1994-3088	A 19940117

OTHER SOURCE(S): MARPAT 125:212684  
 IT 56617-74-4D, derivs. 150515-00-7 150515-01-8  
 150515-03-0 150515-04-1 150515-05-2  
 150515-06-3 150515-07-4 150515-08-5  
 150515-09-6 150515-10-9 150515-11-0


L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN

(Continued)

150515-12-1 150515-13-2 150515-14-3  
 150515-15-4 150515-16-5 150515-17-6  
 150515-19-8 150515-59-6 150515-60-9  
 150515-62-1 181237-78-5 181237-79-6  
 181237-80-9 181237-81-0 181237-82-1  
 181237-83-2 181237-84-3 181237-85-4  
 181237-86-5 181237-87-6 181237-88-7  
 181237-89-8 181237-90-1 181237-91-2  
 181237-92-3 181237-93-4 181237-94-5  
 181237-95-6 181237-96-7 181237-97-8  
 181237-98-9 181237-99-0 181238-00-6  
 181238-01-7 181238-02-8 181238-03-9  
 181238-04-0 181238-05-1 181238-06-2  
 181238-07-3 181238-08-4 181238-09-5  
 181238-10-8 181238-11-9 181238-12-0  
 181238-13-1 181238-14-2 181238-15-3  
 181238-16-4 181238-17-5 181238-18-6  
 181238-19-7 181238-20-0 181238-21-1  
 181238-22-2 181238-23-3 181238-24-4  
 181238-25-5 181238-26-6 181238-27-7  
 181238-28-8 181238-29-9 181238-30-2  
 181238-31-3 181238-32-4 181238-33-5  
 181238-34-6 181238-35-7 181238-36-8  
 181238-37-9 181238-38-0 181238-39-1  
 181238-40-4 181238-41-5 181238-42-6  
 181238-43-7 181238-44-8 181238-45-9  
 181238-46-0 181238-47-1 181238-48-2  
 181238-49-3 181238-50-6 181238-51-7  
 181238-52-8 181238-53-9 181238-54-0  
 181238-55-1 181238-56-2 181238-57-3  
 181238-58-4 181238-59-5 181238-60-6  
 181238-59-4 181239-40-7

RL: THU (Therapeutic use); BIO: (Biological study); USES (Uses)  
 (cardiovascular and renal agents contg.  $\beta$ -oxo- $\beta$ -benzenepropanethioamide derivs.)

RN 56617-74-4 HCAPLUS


CN Benzenepropanethioamide, N-methyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)

RN 150515-00-7 HCAPLUS


CN Benzenepropanethioamide, N, $\alpha$ , $\alpha$ , $\alpha$ -tetramethyl- $\beta$ -oxo- (9CI)  
 (CA INDEX NAME)

L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN


(Continued)




RN 150515-06-3 HCAPLUS

CN Benzenepropanethioamide, 4-(1H-imidazol-1-yl)-N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)

RN 150515-07-4 HCAPLUS

CN Benzenepropanethioamide, 3-fluoro-N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)


RN 150515-08-5 HCAPLUS

CN Benzenepropanethioamide, 3-chloro-N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)


RN 150515-09-6 HCAPLUS

CN Benzenepropanethioamide, N, $\alpha$ , $\alpha$ , $\alpha$ -tetramethyl- $\beta$ -oxo- (9CI)  
 (CA INDEX NAME)


L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 150515-01-6 HCAPLUS

CN Benzenepropanethioamide, 4-methoxy-N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)

RN 150515-03-0 HCAPLUS

CN Benzenepropanethioamide, 4-fluoro-N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)

RN 150515-04-1 HCAPLUS


CN Benzenepropanethioamide, 4-bromo-N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)

RN 150515-05-2 HCAPLUS


CN Benzenepropanethioamide, 4-cyano-N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 150515-10-9 HCAPLUS

CN Benzenepropanethioamide, 3-methoxy-N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)

RN 150515-11-0 HCAPLUS

CN Benzenepropanethioamide, 3-(1H-imidazol-1-yl)-N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)


RN 150515-12-1 HCAPLUS

CN Benzenepropanethioamide, 3-(2-iodo-1H-imidazol-1-yl)-N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)


RN 150515-13-2 HCAPLUS

CN Benzenepropanethioamide, N, $\alpha$ , $\alpha$ -trimethyl-3-(2-methyl-1H-imidazol-1-yl)- $\beta$ -oxo- (9CI) (CA INDEX NAME)


L21 ANSWER 35 OF 137 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 150515-14-3 HCPLUS  
CN Benzenepropanethioamide, 3-(1H-imidazol-1-yl)-4-methoxy-N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 150515-15-4 HCPLUS  
CN Benzenepropanethioamide, 4-ethoxy-3-(1H-imidazol-1-yl)-N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 150515-16-5 HCPLUS  
CN Benzenepropanethioamide, 2-(1H-imidazol-1-yl)-N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)


L21 ANSWER 35 OF 137 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 150515-17-6 HCPLUS  
CN Benzenepropanethioamide, N, $\alpha$ , $\alpha$ -trimethyl-2-(2-(1-methylethyl)-1H-imidazol-1-yl)- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 150515-19-8 HCPLUS  
CN Benzenepropanethioamide,  $\alpha$ , $\alpha$ -diethyl-4-(1H-imidazol-1-yl)-N-methyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 150515-59-6 HCPLUS  
CN Benzenepropanethioamide, 3-(2-iodo-1H-imidazol-1-yl)-4-methoxy-N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)


L21 ANSWER 35 OF 137 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 150515-60-9 HCPLUS  
CN Benzenepropanethioamide, 4-methoxy-N, $\alpha$ , $\alpha$ -trimethyl-3-(2-methyl-1H-imidazol-1-yl)- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 150515-62-1 HCPLUS  
CN Benzenepropanethioamide, 4-methoxy-3-(2-methoxy-1H-imidazol-1-yl)-N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 181237-78-5 HCPLUS  
CN Benzenepropanethioamide, N, $\alpha$ -dimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 181237-79-6 HCPLUS  
CN Benzenepropanethioamide, 4-fluoro-N, $\alpha$ -dimethyl- $\beta$ -oxo- (9CI)

L21 ANSWER 35 OF 137 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)  
(CA INDEX NAME)


RN 181237-80-9 HCPLUS  
CN Benzenepropanethioamide, 4-methoxy-N, $\alpha$ -dimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)



RN 181237-81-0 HCPLUS  
CN Benzenepropanethioamide, 2-(1H-imidazol-1-yl)-N, $\alpha$ -dimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 181237-82-1 HCPLUS  
CN Benzenepropanethioamide, 3-(1H-imidazol-1-yl)-N, $\alpha$ -dimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 181237-83-2 HCPLUS  
CN Benzenepropanethioamide, 4-(1H-imidazol-1-yl)-N, $\alpha$ -dimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)


L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 181237-84-3 HCAPLUS  
CN Benzenepropanethioamide, 3-chloro-4-(1H-imidazol-1-yl)-N,N-dimethyl-  
β-oxo- (9CI) (CA INDEX NAME)




RN 181237-85-4 HCAPLUS  
CN Benzenepropanethioamide, α-ethyl-4-(1H-imidazol-1-yl)-N-methyl-  
β-oxo- (9CI) (CA INDEX NAME)




L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 181237-86-5 HCAPLUS  
CN Benzenepropanethioamide, 4-(1H-imidazol-1-yl)-N-methyl-α-(1-  
methylethyl)-β-oxo- (9CI) (CA INDEX NAME)



RN 181237-87-6 HCAPLUS  
CN Benzenepropanethioamide, 4-(1H-imidazol-1-yl)-N-methyl-β-oxo-α-  
propyl- (9CI) (CA INDEX NAME)




RN 181237-88-7 HCAPLUS  
CN Benzenepropanethioamide, α-hexyl-N-methyl-β-oxo- (9CI) (CA  
INDEX NAME)




L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 181237-89-8 HCAPLUS  
CN Benzenepropanethioamide, 4-chloro-N,N,N-trimethyl-β-oxo-  
(9CI) (CA INDEX NAME)



RN 181237-90-1 HCAPLUS  
CN Benzenepropanethioamide, N,N,N-trimethyl-β-oxo-4-  
(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 181237-91-2 HCAPLUS  
CN Benzenepropanethioamide, N,N,N-trimethyl-4-(2-methyl-1H-  
imidazol-1-yl)-β-oxo- (9CI) (CA INDEX NAME)




RN 181237-92-3 HCAPLUS  
CN Benzenepropanethioamide, 4-(2-ethyl-1H-imidazol-1-yl)-N,N,N-  
trimethyl-β-oxo- (9CI) (CA INDEX NAME)


L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 181237-93-4 HCAPLUS  
CN Benzenepropanethioamide, N,N,N-trimethyl-4-(2-(1-methylethyl)-  
1H-imidazol-1-yl)-β-oxo- (9CI) (CA INDEX NAME)



RN 181237-94-5 HCAPLUS  
CN Benzenepropanethioamide, N,N,N-trimethyl-β-oxo-4-(2-  
propyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 181237-95-6 HCAPLUS  
CN Benzenepropanethioamide, 4-(2-iodo-1H-imidazol-1-yl)-N,N,N-  
trimethyl-β-oxo- (9CI) (CA INDEX NAME)

26/12/2006, 10525820e.trn


L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN

(Continued)



RN 181237-96-7 HCAPLUS


CN Benzenepropanethioamide, 4-(2-methoxy-1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181237-97-8 HCAPLUS


CN Benzenepropanethioamide, 4-(2-chloro-1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 181237-98-9 HCAPLUS

CN Benzenepropanethioamide, N,α,α-trimethyl-4-(4-methyl-1H-imidazol-1-yl)-β-oxo- (9CI) (CA INDEX NAME)



RN 181237-99-0 HCAPLUS


CN Benzenepropanethioamide, N,α,α-trimethyl-4-(5-methyl-1H-imidazol-1-yl)-β-oxo- (9CI) (CA INDEX NAME)



L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 181238-00-6 HCAPLUS

CN Benzenepropanethioamide, 4-(4,5-dichloro-1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181238-01-7 HCAPLUS


CN Benzenepropanethioamide, 3-fluoro-4-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181238-02-8 HCAPLUS


CN Benzenepropanethioamide, 3-chloro-4-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 181238-03-9 HCAPLUS

CN Benzenepropanethioamide, 3-bromo-4-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181238-04-0 HCAPLUS


CN Benzenepropanethioamide, 4-(1H-imidazol-1-yl)-3-iodo-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)




RN 181238-05-1 HCAPLUS

CN Benzenepropanethioamide, 3-cyano-4-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 181238-06-2 HCAPLUS  
 CN Benzenepropanethioamide, 4-(1H-imidazol-1-yl)-N,α,α,3-tetramethyl-β-oxo- (9CI) (CA INDEX NAME)




RN 181238-07-3 HCAPLUS  
 CN Benzenepropanethioamide, 3-ethyl-4-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)


L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 181238-08-4 HCAPLUS  
 CN Benzenepropanethioamide, 4-(1H-imidazol-1-yl)-N,α,α-trimethyl-3-(1-methylethyl)-β-oxo- (9CI) (CA INDEX NAME)




RN 181238-09-5 HCAPLUS  
 CN Benzenepropanethioamide, 4-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo-3-propyl- (9CI) (CA INDEX NAME)




L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 181238-10-8 HCAPLUS  
 CN Benzenepropanethioamide, 4-(1H-imidazol-1-yl)-3-methoxy-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)




RN 181238-11-9 HCAPLUS  
 CN Benzenepropanethioamide, 3-ethoxy-4-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)




RN 181238-12-0 HCAPLUS  
 CN Benzenepropanethioamide, 4-(1H-imidazol-1-yl)-N,α,α-trimethyl-3-(1-methylethoxy)-β-oxo- (9CI) (CA INDEX NAME)


L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 181238-13-1 HCAPLUS  
 CN Benzenepropanethioamide, 4-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo-3-propanoyl- (9CI) (CA INDEX NAME)




RN 181238-14-2 HCAPLUS  
 CN Benzenepropanethioamide, 4-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 181238-15-3 HCAPLUS  
 CN Benzenepropanethioamide, 3-(2-ethyl-1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)




RN 181238-16-4 HCAPLUS  
CN Benzenepropanethioamide, N, $\alpha$ , $\alpha$ -trimethyl-3-(2-(1-methylethyl)-1H-imidazol-1-yl)- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 181238-17-5 HCAPLUS  
CN Benzenepropanethioamide, N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo-3-(2-propyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 181238-18-6 HCAPLUS  
CN Benzenepropanethioamide, 3-(2-methoxy-1H-imidazol-1-yl)-N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 181238-19-7 HCAPLUS  
CN Benzenepropanethioamide, 3-(2-chloro-1H-imidazol-1-yl)-N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 181238-20-0 HCAPLUS  
CN Benzenepropanethioamide, N, $\alpha$ , $\alpha$ -trimethyl-3-(4-methyl-1H-imidazol-1-yl)- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 181238-21-1 HCAPLUS  
CN Benzenepropanethioamide, N, $\alpha$ , $\alpha$ -trimethyl-3-(5-methyl-1H-imidazol-1-yl)- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 181238-22-2 HCAPLUS  
CN Benzenepropanethioamide, 3-(4,5-dichloro-1H-imidazol-1-yl)-N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 181238-23-3 HCAPLUS  
CN Benzenepropanethioamide, 4-fluoro-3-(1H-imidazol-1-yl)-N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 181238-24-4 HCAPLUS  
CN Benzenepropanethioamide, 4-chloro-3-(1H-imidazol-1-yl)-N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 181238-25-5 HCAPLUS  
CN Benzenepropanethioamide, 4-bromo-3-(1H-imidazol-1-yl)-N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 181238-26-6 HCAPLUS  
CN Benzenepropanethioamide, 3-(1H-imidazol-1-yl)-4-iodo-N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 181238-27-7 HCAPLUS  
CN Benzenepropanethioamide, 4-cyano-3-(1H-imidazol-1-yl)-N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 181238-28-8 HCAPLUS  
CN Benzenepropanethioamide, 3-(1H-imidazol-1-yl)-N,N,N-trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 181238-29-9 HCAPLUS  
CN Benzenepropanethioamide, 4-ethyl-3-(1H-imidazol-1-yl)-N,N,N-trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 181238-30-2 HCAPLUS  
CN Benzenepropanethioamide, 3-(1H-imidazol-1-yl)-N,N,N-trimethyl-4-(1-methylethyl)- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 181238-31-3 HCAPLUS  
CN Benzenepropanethioamide, 3-(1H-imidazol-1-yl)-N,N,N-trimethyl- $\beta$ -oxo-4-propyl- (9CI) (CA INDEX NAME)




RN 181238-32-4 HCAPLUS  
CN Benzenepropanethioamide, 3-(1H-imidazol-1-yl)-N,N,N-trimethyl-4-(1-methylethoxy)- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 181238-33-5 HCAPLUS  
CN Benzenepropanethioamide, 3-(1H-imidazol-1-yl)-N,N,N-trimethyl- $\beta$ -oxo-4-propoxy- (9CI) (CA INDEX NAME)




RN 181238-34-6 HCAPLUS  
CN Benzenepropanethioamide, 3-(1H-imidazol-1-yl)-N,N,N-trimethyl- $\beta$ -oxo-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 181238-35-7 HCAPLUS  
CN Benzenepropanethioamide, N,N,N-trimethyl-2-(2-methyl-1H-imidazol-1-yl)- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 181238-36-8 HCAPLUS  
CN Benzenepropanethioamide, 2-(2-ethyl-1H-imidazol-1-yl)-N,N,N-trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 181238-37-9 HCAPLUS  
CN Benzenepropanethioamide, N,N,N-trimethyl- $\beta$ -oxo-2-(2-propyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)



RN 181238-38-0 HCAPLUS  
CN Benzenepropanethioamide, 2-(2-iodo-1H-imidazol-1-yl)-N,N,N-trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 181238-39-1 HCAPLUS  
CN Benzenepropanethioamide, 2-(2-methoxy-1H-imidazol-1-yl)-N,N,N-trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 181238-40-4 HCAPLUS  
CN Benzenepropanethioamide, 2-(2-chloro-1H-imidazol-1-yl)-N,N,N-trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)

26/12/2006, 10525820e.trn


L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 181238-41-5 HCAPLUS  
CN Benzenepropanethioamide, N, $\alpha$ , $\alpha$ -trimethyl-2-(4-methyl-1H-imidazol-1-yl)- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 181238-42-6 HCAPLUS  
CN Benzenepropanethioamide, N, $\alpha$ , $\alpha$ -trimethyl-2-(5-methyl-1H-imidazol-1-yl)- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 181238-43-7 HCAPLUS  
CN Benzenepropanethioamide, 2-(4,5-dichloro-1H-imidazol-1-yl)-N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)




L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 181238-48-2 HCAPLUS  
CN Benzenepropanethioamide, 3-cyano-2-(1H-imidazol-1-yl)-N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)



RN 181238-49-3 HCAPLUS  
CN Benzenepropanethioamide, 2-(1H-imidazol-1-yl)-N, $\alpha$ , $\alpha$ ,3-tetramethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)



RN 181238-50-6 HCAPLUS  
CN Benzenepropanethioamide, 3-ethyl-2-(1H-imidazol-1-yl)-N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 181238-51-7 HCAPLUS  
CN Benzenepropanethioamide, 2-(1H-imidazol-1-yl)-N, $\alpha$ , $\alpha$ -trimethyl-3-(1-methylethyl)- $\beta$ -oxo- (9CI) (CA INDEX NAME)


Young, Shawquia, Page 26

L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 181238-44-8 HCAPLUS  
CN Benzenepropanethioamide, 3-fluoro-2-(1H-imidazol-1-yl)-N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)



RN 181238-45-9 HCAPLUS  
CN Benzenepropanethioamide, 3-chloro-2-(1H-imidazol-1-yl)-N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 181238-46-0 HCAPLUS  
CN Benzenepropanethioamide, 3-bromo-2-(1H-imidazol-1-yl)-N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)




RN 181238-47-1 HCAPLUS  
CN Benzenepropanethioamide, 2-(1H-imidazol-1-yl)-3-iodo-N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)


L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 181238-52-8 HCAPLUS  
CN Benzenepropanethioamide, 2-(1H-imidazol-1-yl)-N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo-3-propyl- (9CI) (CA INDEX NAME)



RN 181238-53-9 HCAPLUS  
CN Benzenepropanethioamide, 2-(1H-imidazol-1-yl)-3-methoxy-N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)






RN 181238-54-0 HCAPLUS  
CN Benzenepropanethioamide, 3-ethoxy-2-(1H-imidazol-1-yl)-N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)







RN 181238-55-1 HCAPLUS  
CN Benzenepropanethioamide, 2-(1H-imidazol-1-yl)-N, $\alpha$ , $\alpha$ -trimethyl-

L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN  
3-(1-methylethoxy)- $\beta$ -oxo- (9CI) (CA INDEX NAME)

(Continued)

RN 181238-56-2 HCAPLUS  
CN Benzenepropanethioamide, 2-(1H-imidazol-1-yl)-N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo-3-propoxy- (9CI) (CA INDEX NAME)RN 181238-57-3 HCAPLUS  
CN Benzenepropanethioamide, 2-(1H-imidazol-1-yl)-N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)RN 181238-58-4 HCAPLUS  
CN Benzenepropanethioamide,  $\alpha$ , $\alpha$ -diethyl-3-fluoro-4-(1H-imidazol-1-yl)-N-methyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 181238-59-5 HCAPLUS  
CN Benzenepropanethioamide,  $\alpha$ , $\alpha$ -dihexyl-4-(1H-imidazol-1-yl)-N-methyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)RN 181238-60-8 HCAPLUS  
CN Benzenepropanethioamide,  $\alpha$ -hexyl-4-(1H-imidazol-1-yl)-N, $\alpha$ -dimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
ED Entered STN: 07 Sep 1996RN 181239-39-4 HCAPLUS  
CN Benzenepropanethioamide, 4-ethyl-3-(2-iodo-1H-imidazol-1-yl)-N, $\alpha$ , $\alpha$ -trimethyl- $\beta$ -oxo- (9CI) (CA INDEX NAME)RN 181239-40-7 HCAPLUS  
CN Benzenepropanethioamide, 4-ethyl-N, $\alpha$ , $\alpha$ -trimethyl-3-(2-methyl-1H-imidazol-1-yl)- $\beta$ -oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 36 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 07 Sep 1996

AB The relative absorption coeffs. Arel = A( $\lambda$ 1)/A( $\lambda$ 2) at various fixed wavelengths used in the UV detection of organic compds. are superior in information content to chromatog. retention indexes of reversed-phase HPLC. To choose standard wavelengths, these coeffs. may

be recommended for inclusion in data bases of anal. parameters designed for the identification of unknown compds. Also, Arel is useful for revealing the nature of chromophores in organic mols., as well as for the group identification of compds. from different groups of structural analogs.

ACCESSION NUMBER: 1996:535941 HCAPLUS

DOCUMENT NUMBER: 125:291931

TITLE: Relative absorption at different wavelengths as a complementary UV-spectroscopic parameter for the identification of organic compounds by reversed-phase high-performance liquid chromatography

AUTHOR(S): Zenkevich, I. G.; Kosman, V. M.

CORPORATE SOURCE: St. Petersburg Inst. Chem. Pharmacol., St.

Petersburg,

SOURCE: 197376, Russia

Journal of Analytical Chemistry (Translation of Zhurnal Analiticheskoi Khimii) (1996), 51(8), 802-806

PUBLISHER: MAIK Nauka/Interperiodica

DOCUMENT TYPE: Journal

LANGUAGE: English


IT 182880-27-9

RL: ANT (Analyte); ANST (Analytical study)  
(organic compds. identification by reversed-phase HPLC using relative

UV absorption coeffs.)

RN 182880-27-9 HCAPLUS


CN 1-Butanone, 3-(methylamino)-1-phenyl- (9CI) (CA INDEX NAME)



L21 ANSWER 37 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 10 Aug 1996  
 GI


L21 ANSWER 37 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 RN 181574-65-2 HCAPLUS  
 CN Benzenepropanamide, N, $\alpha$ -dimethyl- $\beta$ -oxo-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 181574-66-3 HCAPLUS  
 CN Benzenepropanamide,  $\alpha$ -ethyl-N-methyl- $\beta$ -oxo-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 181574-67-4 HCAPLUS  
 CN Benzenepropanamide, N-methyl- $\beta$ -oxo- $\alpha$ -(phenylmethyl)-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



AB After deprotonation with LDA, 2-acyl-3-phenyl-1-menthopyrazoles I (R1 = Me, Et, CHMe<sub>2</sub>, Ph, PhCH<sub>2</sub>) were diastereomerically  $\alpha$ -acylated to give N-(3-phenyl-1-menthopyrazolyl)  $\beta$ -keto amides II (R2 = Ph, Et, Me, CHMe<sub>2</sub>, CMe<sub>3</sub>, 4-MeC<sub>6</sub>H<sub>4</sub>). The subsequent amides were converted into the corresponding N-alkyl amides III (X = NHMe, NHCH<sub>2</sub>Ph, pyrrolidino) retaining their enantiomeric enrichment on the  $\alpha$ -position. These are the first examples of enolizable  $\beta$ -keto acid deriva. having only one chiral center at the  $\alpha$ -position. These chiral  $\beta$ -keto amides were surprisingly stable in dry benzene and their optical asymmetries were almost retained for two weeks at room temperature without any epimerization.

ACCESSION NUMBER: 1996:474764 HCAPLUS  
 DOCUMENT NUMBER: 125:247327  
 TITLE: Enantiomerically enriched preparation of enolizable  $\beta$ -keto amides. Diastereoselective  $\alpha$ -acylation and subsequent aminolysis of 2-acyl-3-phenyl-1-menthopyrazoles  
 AUTHOR(S): Kashima, Choji; Fukuchi, Iwao; Takahashi, Katsumi; Hosomi, Akira  
 CORPORATE SOURCE: Dep. Chem., Univ. Tsukuba, ibaraki, 305, Japan  
 SOURCE: Tetrahedron (1996), 52(31), 10335-10346  
 CODEN: TETRAB; ISSN: 0040-4020  
 PUBLISHER: Elsevier  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 181574-65-2P 181574-66-3P 181574-67-4P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of  $\beta$ -keto amides via stereoselective acylation and aminolysis of acylphenylmenthopyrazoles)